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Abstract 
Introduction: 
Respiratory Syncytial Virus (RSV) is a leading cause of lower respiratory 
symptoms in infants, the elderly and the immunosuppressed worldwide. 
Approximately 70% of children become infected with RSV during their first year of 
life, and by the age of three almost all children will have been exposed to the 
virus. Approximately 2-3% of RSV infected infants require hospital admission. The 
aims of my MPhil project were as follows: 
 To determine whether I could ‘knockdown’ using siRNA, the expression of 
26 innate resistance genes in airway epithelial cells, previously known to 
limit influenza.. 
 To determine which genes provide protection against both influenza and 
RSV, by infecting ‘knockdown’ cultured epithelial cells with RSV, and 
measuring viral replication and RSV N gene expression. 
 To further investigate the significance of these results by focusing on three 
of these genes in more detail. 
Methods: 
SiRNA was used to knockdown genes in A549 cell cultures. They were infected 
with RSV A2 strain two days after siRNA transfection, and a further two days later,  
mRNA was extracted and isolated from the cells. These samples were reverse 
transcribed, and RSV N gene expression analysed through real-time PCR.  
Further study on genes required the use of antibody staining, fluorescent-labelled 
RSV and confocal microscopy. 
Results: 
Initially, PCR assays were optimised and quantitative, and RSV concentration was 
standardised. Efficiency of siRNA reagent was proved with gene expression 
knocked down > 60%. Following RSV infection of these knocked down cultures, 
20/26 genes were found to up-regulate RSV N gene expression after their gene 
expression had been reduced. Two genes (RNF168 and RFFL) caused a large 
increase in RSV expression after knockdown and so were investigated further as 
well as, UBE2G2, an associated protein, identified through an online database. 
Unfortunately, the impressive changes in RSV replication previously seen on 
knocking down RNF168 and RFFL could not be repeated, and UBE2G2 was 
found to have little effect on RSV replication. GPR34, which when knocked down 
caused morphological changes on light microscopy, was also studied further using 
red fluorescent-labelled RSV and antibodies. This protein was found to be located 
around the periphery of the cell and possibly around the nucleus, with protein 
knockdown causing blebbing of the cell membrane. 
Discussion: 
This work has shown that 20/26 genes previously reported to offer some 
protection against influenza, also provide some protection against RSV. These 
findings further our understanding of the pathogenesis of RSV disease, and 
highlight possible avenues for future therapeutic research. These might involve 
increasing expression of these 'innate resistance genes' in the respiratory 
epithelium. 
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1  Introduction 
1.1 Respiratory Syncytial Virus (RSV) 
Respiratory Syncytial Virus (RSV) is a leading cause of lower respiratory 
symptoms in infants, the elderly and the immunosuppressed worldwide (1-5). 
It is one of two human pneumoviruses within the Paramyxoviridae family (1, 
6). RSV causes bronchiolitis, a condition of infants with high hospital 
admission rates, characterised clinically by fever, nasal discharge and dry, 
wheezy cough (7, 8). 
1.1.1  Discovery of RSV 
In 1857, Eberle described an infant disease with cough, wheezing and 
respiratory difficulty. Although, at the time it was unknown what caused the 
illness, this is now thought to be the first clinical description of RSV infection  
(9). Nearly 100 years later, Adams investigated several epidemics of serious 
respiratory disease in infants with cough, dyspnoea and cyanosis. A viral 
cause for these symptoms and signs was suggested following the sudden 
outbreak of disease and negative bacteriology results (10, 11). In 1955, 
Blount et al described copious nasal discharge and sneezing, within a group 
of chimpanzees that were kept for research purposes. From this discharge 
they isolated a virus that they entitled “chimpanzee coryza agent” (CCA) (12). 
During this time a laboratory worker, who worked with the chimpanzees, also 
fell ill with similar respiratory problems and tests showed positive CCA 
antibody titres (12).  In the following year, Chanock et al found that a virus 
affecting infants with lower respiratory tract disease was indistinguishable 
from CCA in laboratory tests. They concluded that CCA was capable of 
causing human disease (13). Notably, Chanock was also able to show the 
“formation of syncytia or pseudo large cells” when cultured human epithelial 
cells were infected with this organism, and suggested that “Respiratory 
Syncytial Virus” would be a better name than CCA (14). Chanock identified 
several characteristics of RSV: 1) RSV is a leading cause of bronchiolitis and 
pneumonia in infants and young children, 2) Annual epidemics during the 
winter months occur and last between three and five months, 3) Almost 
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100% of children are infected with RSV by the age of four years, and 4) 
Reinfection does occur later in life, but usually manifests as a milder disease 
(14, 15). 
1.1.2  Epidemiology of RSV Infection 
RSV is a common infection. During the first year of life approximately 70% of 
children become infected with RSV, and by the age of three almost all 
children will have been exposed to the virus, with around 50% having been 
infected more than once  (1, 6, 7, 16-22). Mild RSV infection normally results 
in an Upper Respiratory Tract Infection (URTI), which resolves without the 
need to seek medical attention (17, 22). Severe RSV disease is due to Lower 
Respiratory Tract Infection (LRTI), and in infants manifests commonly as 
bronchiolitis. Hospitalisation occurs in 2-3% of all infants infected with RSV 
(18, 22-24). Hospital admission rates due to RSV have increased over the 
last few decades, with the peak age of admission being between 2.5 and 4 
months (6, 7, 25, 26). Krishnan reported that morbidity is highest during the 
first six months of life, and that infection under two months of age is rare (17). 
USA figures show that of the children hospitalised with bronchiolitis, 15-35% 
require admission to paediatric intensive care unit (PICU) and 9% are in need 
of mechanical ventilation (7, 23). In the UK, Crowcroft et al investigated 
admission length of stay for RSV-infected infants in five London PICUs. The 
mean duration of ventilation was 4.4 days, the length of admission in PICU, 
8.6 days and length of hospitalisation, 15.9 days (27). The highest proportion 
of children needing HDU/PICU care had predisposing conditions such as 
congenital heart disease and chronic lung disease secondary to prematurity. 
Graham reported that every year over 30 million children under the age of 
five are infected with RSV globally, with over three million of these needing 
hospitalisation (6). Fortunately Bronchiolitis-associated deaths are relatively 
rare in the developed world. However, worldwide, RSV is responsible for 
approximately 160,000 deaths annually for children under the age of five (7, 
8, 28). In the UK, bronchiolitis mortality rates have dropped from 21.47 per 
100,000 live-births to 1.82 per 100,000 live-births, between 1979 and 2000 
(29). The RSV-attributed winter mortality rate for infants secondary to 
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respiratory causes, averaged over eleven winters, were 2.9 per 100,000 
cases, relative to 8.4 per 100,000 cases for all causes (29). In the USA, 
120,000 infants are hospitalised with RSV infection each year, with a post-
neonatal mortality rate, due to RSV, of 2.0 per 100,000 live-births. The 
annual economic impact of RSV infection in infants in the USA is 600-750 
million USD (1, 7, 15, 22, 28, 29). 
Predictable seasonal RSV epidemics and consequent cases of bronchiolitis 
are found globally. The disease occurs annually, but the exact months vary 
slightly each year and between the different countries. In the Northern 
Hemisphere including the UK and Northern Europe, RSV cases peak 
annually in the winter months, usually between December and January. In 
the USA, infection begins during late December in the South, spreading 
throughout, and finally finishing in the Midwest. RSV rates peak throughout 
the cool dry season in South America and South Africa, which is comparable 
to tropical areas located north of the Equator, where the epidemic is during 
the cool rainy season. In temperate climates RSV infection tends to be 
highest during the winter months, with the exception of Hong Kong, where it 
peaks during spring or summer (29). 
As RSV bronchiolitis is predominantly a paediatric condition, the impact of 
RSV disease in the elderly is easily overlooked. Although this is not a focus 
of this thesis, it is worth noting that in the USA, RSV causes 12,000 to 14,000 
deaths annually and hospitalises 200,000 to 400, 000 over-65 year olds (4, 
6).  
Figure 1.1 shows the yearly and seasonal variation of RSV bronchiolitis case 
reports received from England and Wales. Figure 1.2 illustrates the weekly 
variation of RSV bronchiolitis cases by the date of the specimen and the age 
of the patient. 
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Figure 1-1: Seasonal and Yearly Variation of RSV Bronchiolitis Case Reports 
 
 
 
 
 
 
 
 
 
 
 
 
The seasonal and yearly variation of RSV bronchiolitis case reports received by the 
Health Protection Agency Collindale of Infections between 1991 and 2012, four 
weekly, in England and Wales. 
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Figure 1-2: Weekly Variation of RSV Bronchiolitis by Age of Patient 
 
 
 
The weekly variation of RSV bronchiolitis case reports by date of specimen and age 
of patient, received by Health Protection Agency from NHS and HPA laboratories 
from October 2011. 
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1.1.3  Clinical Features of RSV 
RSV is known to cause a broad spectrum of disease, which can vary from 
mild coryzal symptoms to life-threatening bronchiolitis and pneumonia (1, 
30). Almost all infants and young children will initially present with the signs 
and symptoms of a mild URTI. The three most common symptoms include 
cough, rhinorrhoea and a low-grade fever (19, 26, 31-33).  
Zuccotti and Manoha both undertook prospective studies to investigate the 
clinical symptoms present in RSV infected infants and children. Zuccotti's 
study was based in two paediatric clinics in the hospitals associated with 
University of Milan, Italy, and took place for one year from December 2008, 
involving children aged 0 to 15 years (31). Manoha's trial began in December 
2002 and was completed in April 2004, retrieving participants under the age 
of two, from the Paediatric Emergency Care Unit in the Hospital of Dijon, 
France (32).  
Zuccotti found that 100% of the patients (n=178) had cough and rhinorrhoea, 
whereas Manoha’s patients (n=238), 73.1% had a cough and 68.9% 
rhinorrhoea. Fever and feeding difficulties were respectively reported in 71% 
and 68% of patients by Zuccotti and in 37.8% and 55.9% in Manoha (31, 32). 
Other features reported were wheeze, feeding difficulties and sneezing (19, 
26, 29, 33). Usually these symptoms resolved within weeks, with the most 
common acute complications of an RSV bronchiolitis being acute otitis media 
and apnoea (29).  
Approximately 40-50% of infants infected with RSV develop lower respiratory 
tract signs and symptoms but most of these children remain relatively well. 
However, 4-5% do develop more severe lower respiratory symptoms and 
signs that include apnoea, hypoxia, respiratory difficulty (shallow, rapid 
breathing, nasal flaring, grunting, tracheal tug and intercostal recession), 
head bobbing and characteristic cough (6, 19, 33-35).  
A diagnosis of bronchiolitis is usually made by looking for the presence of the 
above signs and symptoms, and for the characteristic fine inspiratory 
crackles and/or high pitched expiratory wheeze heard on auscultation (35). 
Investigations are often not needed apart from confirmation of RSV status for 
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cohorting purposes on medical wards. Chest x-rays are not routinely 
recommended for typical cases of bronchiolitis as they do not add to clinical 
management (35). That said, RSV can cause numerous abnormal findings in 
a chest x-ray, including non-specific hyperinflation (Figure 1.3), atelectasis 
and infiltrates. It is important though for the clinician to remember that a RSV-
positive patient can present with a normal chest x-ray (19, 29, 35). 
Measurement of respiratory rate and oxygen saturations, both non-invasive 
procedures, provide vital information necessary for the management of 
children with bronchiolitis (19, 29). These and other clinical indices are often 
incorporated into bronchiolitis care pathways (Figure 1.4) to standardise the 
management of these children. 
For the 2-3% of RSV-infected children who require hospitalisation, causes 
include hypoxia, inadequate fluid intake, apnoea and signs of respiratory 
failure on blood gases. CO2 retention is a very late complication of RSV 
bronchiolitis, which will present with irritability, cyanosis, lethargy and 
exhaustion (35). 
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Figure 1-3: Abnormal Chest X-Ray caused by RSV Bronchiolitis  
 
 
 
 
 
 
 
 
 
 
 
This image was kindly provided by Dr. P. McNamara. The chest x-ray from an infant 
with RSV bronchiolitis shows air trapping and hyperinflation. 
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Figure 1-4: Alder hey Children's hospital Bronchiolitis Care Pathway 
Infants up to 24 months via GP or self referral to A & E
Bronchiolitis - Care Pathway Flow Chart
Life ThreateningMild Moderate/Severe
Respiratory Assessment categorise severity of symptoms to
Nasopharyngeal aspirate
Oxygen to maintain SaO2 >92%
Discharge criteria met
Temp. < 38
o
pa
Taking ¾ usual feed
SaO2 in air above 92%
Resp. rate below  50/min 
Pulse rate below 140/min
RSV leaflet
Explain home care required
Arrange appropriate follow  up
GP letter
HV liaison
Yes
No
Admit
following cohort policy
Oxygen SaO2  to maintain >92% 
Follow pathway feeding regime
Admit
Oxygen to maintain SaO2 >92%
Nil by mouth, I.V. fluids
U & E’s  CXR
Temp. > 38
o
(pa)  - FBC
blood culture
Consider antibiotic therapy 
Discharge home
Symptoms Improving
Yes
No
Discharge criteria met for 12hrs
Temp. < 38o pa
SaO2 in air above 92%
Oral feeding only
Fluid intake > 120ml/kg or if  >6mths 
and mixed feeding  >600ml/day
Suction not required
Symptoms ImprovingYes
Oxygen to maintain SaO2 >92% 
Ventilatory support,as indicated
Inform anaesthetist 
Consider capillary gases
Nasopharyngeal aspirate when possible
Consider transfer to I.T.U
Transfer
according to cohort policy
Pathway feeding regime
No
NPA result known
Transfer according to cohort policy
Objective evidence of bacterial infection
commence antibiotic therapy
Consider transfer to I.T.U
Royal Liverpool Children’s NHS Trust
Alder Hey
Bronchfc2.ppt2002
NHS
 
This care pathway is kindly supplied by Dr. P. McNamara. It is followed for any 
infants up the age of 24 months presenting to the Accident and Emergency 
Department with signs and symptoms of RSV bronchiolitis. The severity of the 
disease must be determined immediately and the steps followed to ensure correct 
investigations and management is given at all times. 
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The effects of RSV are not just limited to the acute infection. Several studies 
report that wheezy episodes are much more common following RSV infection 
in early life, especially following severe disease (36, 37). Also, recurrent 
wheeze secondary to RSV infection has also been associated with the 
development of airway hyper-responsiveness  (2, 37, 38). Stein et al 
investigated this association in children who had confirmed RSV lower 
respiratory illness up to the age of three (39). The results confirmed that 
there was a significant increased risk of developing recurrent wheeze, after 
an RSV lower respiratory tract illness, in the first ten years of life, which 
gradually decreased with age, becoming insignificant by thirteen years (39). 
This pattern was also similar when other lower respiratory tract infections 
were investigated, but the results were less marked and less consistent than 
those for RSV. Two other findings in children that had had RSV LRTI 
included lower lung function during their school years if they were diagnosed 
with RSV bronchiolitis in their infant years, and increased responsiveness to 
bronchodilators at age eleven. Stein et al suggested that disruption of airway 
tone could explain this association, where the tone improves with age, 
explaining the weakening of this link (39). Conversely, Sigurs et al undertook 
a prospective study following hospitalised infants with RSV bronchiolitis (91% 
< 6 months) up to the age of 13. The findings showed that severe RSV 
infection in early infancy was a strong risk factor for developing asthma up to 
and during early adolescence. At the age of 13, 43% of the RSV group 
(n=46) had current asthma and recurrent wheezing compared to 7.6% of the 
control group (n=92), with a p value of < 0.001 (40). These differences 
between Stein and Sigurs results may be due to a number of reasons. 
Sigurs’ participants were all hospitalised during RSV infection, and all below 
the age of one, showing that they may have extracted more severe RSV 
bronchiolitis. The variation in population (Sigurs’ study was based in Swedan, 
whereas Stein was in USA), climate factors and allergen load (as 28% of 
Sigurs’ control group had positive skin prick tests, compared to 59% found in 
Stein’s project) could also have contributed to the difference in results (39, 
40). 
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An important feature of RSV infection is that sustained protective immunity 
does not occur and re-infection may arise at anytime of the patient’s life, 
regardless of the presence of the serum antibody (26, 29). Usually re-
infection will cause milder disease (6, 15).  
1.1.4  Risk Factors in RSV Infection 
Although all infants and young children are susceptible to RSV infection, 
various factors can make an individual “high risk”, and more likely to be 
hospitalised (41). The following predisposing conditions significantly increase 
the risk of severe bronchiolitis (6, 7, 19, 23, 29, 38, 41-43).  
1.1.4.1 Premature Infants 
Premature infants (gestational age < 35wks) are prone to severe RSV 
disease and particularly, severe bronchiolitis, because of their immature 
immune system. Most maternal antibody transfer occurs during the third 
trimester. This transfer is incomplete in preterm infants and thus they have 
lower serum concentration of IgG antibodies and are at higher risk of 
succumbing to infections (44-46). Other factors probably also play a role. For 
instance, the quantity and quality of the neutrophils and complement in 
preterm infants are significantly reduced compared to their full-term peers. 
Generally the child is fully immunocompetent by six months of life (44, 45).  
1.1.4.2 Chronic Lung Disease of Prematurity 
Chronic lung disease (CLD) of prematurity is also a predisposing factor for 
RSV infection because the respiratory system is abnormally developed (44).  
Much of the lung development occurs in the third trimester. At 30 weeks 
gestation the lung volume is only 34% of the final volume at term, and the 
airspace walls are much thicker at 28μm, compared to the term 
measurement of 17μm (47). This reduces compliance, flow and gas 
exchange ability within the lungs. An increased risk of airway obstruction, 
secondary to the reduced size of the airway and the increased production of 
mucus and dislodging of the necrotic tissue within the lungs, is another 
factor. Airway obstruction prevents the removal of secretions from the lower 
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airways, providing an ideal environment for infection (both viral and bacterial) 
to occur (45). 
1.1.4.3 Congenital Heart Disease 
Congenital heart disease (CHD) is the third major risk factor that predisposes 
infants to severe RSV bronchiolitis, especially if it causes pulmonary 
hypertension (48). Kristensen et al’s case-control study assessed the risk 
factors for RSV hospitalisation in children diagnosed with heart disease (49). 
The study was based in Denmark, using a database to select children 
diagnosed with both RSV and heart disease. Each patient was then paired 
with a control at the same age resulting in a total of 313 pairs. The major risk 
factors found were Down's syndrome (Section 1.1.4.4) and Cardiomyopathy 
(OR 5.84). Haemodynamically significant heart disease (OR 1.53) had a 
lesser effect, but was found to still be statistically significant in the study. 
Young age and cardiac decompensation were both related to increased 
severity of RSV infection and the need for respiratory intervention (49).  
Alexander et al also undertook an observation cohort study in Australia, 
searching institutional databases between 2005-09 (50). Participants were 
children admitted with RSV bronchiolitis whom had a previous diagnosis of 
symptomatic cardiac disease (SCD), defined as haemodynamic significant 
cyanotic or acyanotic CHD, pulmonary hypertension or hypertrophic 
cardiomyopathy. Results showed that patients with SCD were more likely to 
be admitted secondary to RSV infection, and have a more complicated and 
lengthy stay in hospital, requiring PICU admission and respiratory support. 
Data showed that SCD made up 2-9% of the total RSV admissions and of 
those admitted, around 20% required PICU attention (50).  
1.1.4.4 Genetic and Chromosomal Abnormalities 
Down's syndrome, trisomy 21, is the most common chromosomal 
abnormality among live-born infants, and is characterised by various 
dysmorphic features and congenital malformations such as CHD and 
gastrointestinal disease (51). As mentioned in the previous section, 
Kristensen completed a case-control study to find that Down’s syndrome was 
the largest risk factor, when comparing RSV and heart disease, with an OR 
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of 3.24. Children with Down’s syndrome showed they were more susceptible 
to obtaining RSV, but other factors that might contribute are immature lung 
development, abnormal airway structure or the disturbance within the 
immune response. All these features are commonly seen within children 
suffering with Down’s syndrome (49). 
Bloemers also reviewed the vulnerability of children, diagnosed with Down’s 
syndrome, of obtaining RSV infection. Patients with Down’s syndrome alone 
had an increased chance of hospital admission secondary to RSV by ten-
fold, compared to patients without Down’s. Similar to above, Down’s 
syndrome patients with haemodynamically significant CHD are two times 
more likely to be admitted than patients who suffer from haemodynamic 
significant CHD, but do not have Down’s syndrome. The factors causing this 
are similar to those mentioned by Kristensen, but Bloemers also added 
atypical swallowing and aspiration, secondary to hypotonia (51).  
Cystic Fibrosis (CF) is an autosomal recessive genetic disorder, which 
results in increased mucus viscosity and thus impairing lung function. CF 
patients are prone to extracting respiratory infections, including RSV. During 
an acute pulmonary exacerbation secondary to a respiratory virus, CF 
patients have a four-fold increased risk of developing a LRTI, and then 
needing hospital admission. During infancy, RSV infection within CF patients 
makes up approximately one third of admissions. There is some evidence 
that CF patients diagnosed with RSV LRTI may have impaired lung function 
for a number of months following the illness, but further investigation within 
this area is required (52). 
1.1.4.5 Immuno-compromise 
RSV infection in the immunocompromised can be very serious. Ebbert 
undertook a study with eleven RSV infected patients with underlying immuno-
compromise (53). He found that their chest radiographs displayed patchy or 
nodular alveolar infiltrates throughout the lung, compared to the interstitial 
infiltrates expected. Over 50% of the patients required intubation and 
ventilation on intensive care, and six out of the eleven patients died, later to 
be diagnosed with RSV pneumonitis (53). 
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1.1.4.6 Other Risk Factors 
Other reported risk factors for RSV infection include: male gender, low birth 
weight, chronological age (birth during first half of RSV season), multiple 
birth, not breast fed < two months old, day care attendance, house crowding 
(>4 people living in the house), sibling of school age, self or family history of 
atopy, passive tobacco and environment pollutants exposure and underlying 
neuromuscular disorder  (6, 7, 19, 23, 29, 34, 42, 43, 45, 46, 48).  
1.1.5  Management and Prevention of RSV Infection 
There is a dearth of treatment options for infants with RSV bronchiolitis.  
Currently, management consists of maintaining adequate hydration, 
sometimes with naso-gastric or intravenous fluids, and supplemental oxygen 
(19, 35).  
A Cochrane Review has examined the use of nebulised hypertonic 3% saline 
in the treatment of non-severe acute RSV bronchiolitis among hospitalised 
infants (54). There were a number of reasons why hypertonic saline might 
work in bronchiolitis. Firstly, hypertonic saline is thought to encourage the 
osmotic flow of water towards the mucus layer of the airway, and rehydrate 
the surface liquid and thus provoking mucus clearance. Secondly, the mucus 
gel contains ionic bonds that can be broken by the hypertonic solution, which 
therefore reduces the number of cross-linking, and lowers the viscosity and 
elasticity of the mucus. Lastly, hypertonic saline releases prostaglandin E2, 
which encourages the cilia to beat more efficiently (54).  
The Cochrane group reviewed seven double-blinded, randomised control 
trials of 3% hypertonic saline. The use of hypertonic saline, compared to 
normal saline, significantly shortened the mean length of hospital stay by 
1.16 days in total. The 95% confidence interval was -1.55 to -0.77 with a P 
value of less than 0.00001, showing a 24.1% reduction. The rate of 
hospitalisation and risk of readmission were also assessed, but neither 
produced significant results. The risk of readmission was reduced by 8% 
overall, but the P value equalled 0.82. RSV bronchiolitis is a burden to 
hospitals during its peak onset, so finding this significant benefit in reducing 
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the length of hospital stay could have a positive impact, especially 
economically, for both individual families and the health service (54). 
Another Cochrane review concluded that bronchodilators are unlikely to play 
an important role in the acute treatment of bronchiolitis. They do not improve 
oxygen saturations, need for hospital admission or the number of days of 
hospitalisation (55). Both Fitzgerald and Smyth suggested that epinephrine 
had minimal improvement when used, but the significance of this remained 
uncertain (29, 35). A recent Cochrane review demonstrated that epinephrine 
was superior to placebo during the first 24hours, but there is still no data to 
confirm the effectiveness of administering repeated or prolonged doses (56). 
There have been suggested benefits when combining epinephrine with 
steroids, but this requires more evidence and research before it should be 
put into clinical practice (56). Antibiotics do not have a role in the treatment of 
bronchiolitis either, unless in severe disease where there is potential doubt 
over the diagnosis (23, 57). Ribavirin is a broad spectrum antiviral agent, 
occasionally used in treating immunocompromised children, but evidence for 
benefit is weak and with high cost and safety issues (it is potentially 
teratogenic) it is not generally recommended (29, 35).  
Vaccination development has been thwarted over the last fifty years. A 
formalin-inactivated vaccine against RSV was developed during the 1960s 
and initially proved promising as it produced high serum antibody titre. This 
was soon dismissed as the results from its use in humans showed that the 
vaccine caused an exaggerated and altered clinical response against the 
natural form of RSV. Significantly more people vaccinated with RSV (80%) 
were hospitalised with severe respiratory disease than non-vaccinated 
controls (5%), during the first RSV season following the vaccination. 
Therefore, this shows that the vaccine induced a disturbance within the 
immune reaction (15, 36, 58). 
Palivizumab is a monoclonal antibody used to prevent RSV disease in high-
risk infants. It acts by binding to the neutralising epitope found on the fusion 
protein of the RSV molecule. Due to its expense it is only recommended as 
prophylaxis for high-risk patients (4, 29, 41), and is administered as five 
monthly intramuscular injections over the RSV season (October-March in the 
 16 
UK) (19). The RCPCH guidelines for Palivizumab use states that if the infant 
is under twelve months of age they are eligible for the vaccine if they suffer 
from: 1) extreme prematurity, 2) acyanotic CHD, 3) congenital or acquired 
lung disease and 4) immunodeficiency (19, 59). These guidelines vary 
throughout countries, as the AAP states that the infant must be <32 weeks 
gestation age with two or more risk factors, i.e. day care attendance; or suffer 
from CHD, immunodeficiency, respiratory or neuromuscular disease (43, 60).  
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1.2 Pathogenesis 
1.2.1  RSV Structure and Function 
RSV is an enveloped, single-stranded negative RNA virus that belongs to the 
Paramyxoviridae family. In total it has ten genes, which encode for 11 
proteins, and is 15.2kb in size (1, 16, 19, 20, 30, 61, 62). The sequence order 
of these ten genes is: 3’-NS1-NS2-N-P-M-SH-F-G-M2-L-5’ (Figure 1.5). Of 
the 11 protein products, nine are structured components of the virion and two 
are non-structural proteins (1). 
 
 18 
Figure 1-5: RSV Proteins and Gene Map 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This image shows: A) RSV proteins and B) gene map (taken from Collins et al) (30) 
Section A is a negative-stained image of budding RSV virions under an electron microscope, 
where V is the virion and F is the filamentous cytoplasmic structures. Where known, the RSV 
protein locations and functions have been labelled. Section B shows the gene map of RSV 
A2 strain. The overlapping M2-1 and M2-2 ORFs are shown above the sequence, and the 
numbers below are the nucleotide lengths. The 3’ leader (le) and 5’ trailer (tr) regions are 
labelled, and the underlined numbers are intergenic regions. The numbers above the gene 
map are the amino acid lengths for each protein. The RSV proteins are: NS1, Non-structural 
protein 1; NS2, Non-structural protein2; N, Nucleoprotein; P, Phosphoprotein; M, Matrix 
protein; SH, Small hydrophobic glycoprotein; G, Attachment glycoprotein; F, Fusion 
glycoprotein; M2-1, first ORF in M2 mRNA; M2-2, second ORF in M2 mRNA; and L, Large 
polymerase protein. 
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The mature RSV virion contains a ribonucleoprotein (RNP) complex, which is 
synthesised by links between the viral genomic RNA (vRNA), the 
nucleocapsid (N) protein, the phospho (P) protein and the large (L) protein 
(63). The RSV genome is retained within the helical nucleocapsid, which 
protects the viral genetic information and acts as the viral replication template 
(64, 65). The P protein is a homotetramer phosphoprotein, which is an 
important element of the polymerase complex (30, 62). The viral polymerase 
is reliant on the P protein during transcription for clearance and chain 
elongation (30). The L protein stimulates RNA synthesis, encodes the RNA 
polymerase and has a role in RNA transcription and replication  (16, 30, 62).  
Transcription also requires the M2 protein which encodes for two products: 1) 
M2-1 – transcription factor; 2) M2-2 – transcription regulatory factor. The M2 
mRNA contains two overlapping open reading frames (ORF1 and ORF2). 
ORF1 promotes chain elongation transcription and optimises mRNA 
production, whereas ORF2 regulates the accumulation of genomic and 
antigenomic RNA (16, 30, 62, 66).  
The non-structural genes 1 and 2 (NS1 and NS2) are small proteins, 139 and 
124 amino acids long, respectively (67), whose names were derived because 
they are produced in RSV-infected cells, but are not contained in the mature 
virion structure (68). They counteract the host innate immune response by 
expressing proteins that antagonise the interferon system. They especially 
act by interfering with the induction of type I interferons (IFN), thus causing 
vigorous replication of the virus and resulting in a more severe respiratory 
disease (16, 30, 61-63, 67, 68). Overall there are two functioning interferon 
pathways: 1) induction pathway, where the cells produce IFN; and 2) 
response pathway, in which the cells react to the exogenous IFN (67). 
Individually, NS1 has the greatest IFN inhibiting effect, but these work 
synergistically (68). 
The host immune system has developed an effective antiviral response 
which reduces virus replication and spread. Janus kinases, JAK1 and TYK2, 
are associated with the two subunits for type I IFN receptors. These receptor 
tyrosine kinases are activated and result in tyrosine phosphorylation of signal 
transducer and activator of transcription 2 (STAT2) and STAT1. Once these 
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are activated interferon-stimulated gene factor 3 (ISGF-3) complexes are 
formed, and bind with the IFN-stimulated response elements (ISRE) to begin 
gene transcription and then consequently antiviral immunity (69). 
Both, NS1 and 2 proteins can form functional homo- and heteromers, which 
are able to interfere within the signal transduction pathway, resulting in the 
down-regulation of IFN-β. The IFN-induced signal transduction from its 
receptor is suppressed through the JAK/STAT pathway, initiated by 
proteasomal degradation (30, 67). It is thought that NS2 works in this way, as 
proteasome inhibitor MG132 can inhibit it. The NS1 protein targets the 
STAT2 pathway by synthesising an E3 ligase complex, which then continues 
to degrade the pathway. Both the NS proteins can individually cause STAT2 
degradation, but it is most effective when both proteins are contributing. It 
has been suggested that the NS2 protein may influence the E3 ligase activity 
by stabilising the complex for the NS1 protein to act upon (68, 69). 
Ramaswamy’s work showed that RSV uses the NS2 protein to weaken type I 
IFN antiviral response, and revealed that by inhibiting the STAT2 pathway it 
lowered type I IFN-dependent signalling resulting in reduced gene expression 
(70). 
The M protein is the matrix protein and is located on the inner surface of the 
viral envelope. This protein mediates the interaction between the plasma 
membrane and the RNP during virion synthesis (30, 61, 62). Its positively 
charged crystal structure recently revealed a monomer condensed with N-
terminal and C-terminal domains (30).    
Also within the RSV structure there are three surface glycoproteins; the 
heavily glycosylated G protein, the fusion (F) protein and a small hydrophobic 
(SH) protein.  
The G protein is a type II glycosylated transmembrane protein, approximately 
298 amino acids long (6, 62). It is involved in the attachment of the virus to 
target cells, and is also known as the “attachment glycoprotein” (6, 63). The 
G protein is a target for neutralising antibodies, and has the most variability in 
its structure compared to all the other RSV proteins. These antigenic 
differences are found mostly between the two subgroups of RSV, A and B, 
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where the amino acid sequence can vary by approximately 50% (6, 62, 65). 
These points have initiated research in potential G antigen vaccine designs. 
The protein also has an unusual composition compared to the other 
glycoproteins, because it is made up of around 30% serine and threonine 
and 10% proline (6, 62). The G protein can also be expressed as membrane-
bound and secreted forms, where the latter interferes with antibody-mediated 
neutralisation (16, 30, 65). 
The F protein is a type I glycosylated transmembrane protein involved in viral 
entry and cell-to-cell spread by plasma membrane fusion (6, 16, 62, 63, 71). 
It is made up of 574 amino acids, with a trimeric coiled-coil structure 
comparable to other fusion proteins within viruses (65). The F protein has an 
inactivated form, F0. Cleavage of F0 causes activation to occur forming two 
subunits, F1 and F2, covalently attached by disulphide bonds. It has been 
recently found that both F proteins bind to glycosaminoglycans (GAGs), 
mandatory for efficient RSV infection of cell lines (30). The G and F proteins 
work together to become important protective antigens within the RSV 
molecule, and the major targets for neutralising antibodies (65, 71, 72). 
The G protein attaches the virus onto the respiratory epithelium, whilst the F 
protein supports fusion between both the viral and cell membranes, and the 
infected and adjacent cell membranes, resulting in the movement of genetic 
material, and formation of the syncytia, respectively. These syncytia are 
mandatory for cell-to-cell viral transmission, and are characteristic of the RSV 
cytopathic effect (65). Thus, this describes that RSV directly spreads across 
the respiratory epithelium. 
The SH protein is the third integral transmembrane surface glycoprotein 
whose function still remains unclear. Potential roles as a pentameric ion 
channel and in membrane fusion have been suggested (6, 30, 62, 65). It has 
not been extensively studied other than part of failed attempt to develop a 
vaccine (6).  
1.2.2  RSV Viral Infection and Cytotoxicity  
RSV initially infects the upper respiratory tract, by principally targeting the 
airway epithelial cells, the first line of defence for the body  (16, 36). In those 
 22 
that develop lower respiratory disease, it has an incubation period of two to 
eight days before it spreads to the small bronchiolar epithelium lining (19, 21, 
26). Between one to three days oedema, increased mucus production and 
eventual necrosis and sloughing of the epithelium occur, resulting in small 
airway obstruction (19, 24, 65). Clinically, this causes “air trapping and 
hyperinflation or collapse/atelectasis of distal lung tissue” (24), and can lead 
to hypoxia and respiratory failure (24, 65).   
RSV pathogenesis remains controversial. RSV is a highly contagious virus, 
whose tropism targets the superficial epithelial cells, thus reducing the impact 
of the host response (6, 15, 22). Studies have shown that lung injury can be 
exacerbated by the direct viral damage and the inflammatory responses 
mediated by the virus (1, 73). Monick et al showed that RSV infection caused 
apoptosis of the lung epithelial cells, but only after the cells had released 
inflammatory mediators and conditions favourable for viral replication (16, 
20). Collins also showed that RSV was not highly cytopathic, as he observed 
delayed tissue damage after weeks of infection (30). Interestingly, he noticed 
that ciliary function was soon impaired; again contributing to airway 
obstruction (30). Studies by both Herranz and Martinez show that part of the 
damage caused by RSV is due to the immune response (36, 61). 
1.2.3  The Immune Response to RSV 
The role of the mammalian immune system can be considered to be to 
recognise and remove any unwanted foreign material within the body, whilst 
minimising damage to the host during the immune response (74). The human 
immune system has been classically divided into two separate components 
or systems termed innate and adaptive immunity. The innate system 
provides a first line of defence, which is always present and is also important 
in inducing adaptive immunity. Adaptive immunity by comparison is 
characterised typically by pathogen-specific antibody production and cell-
mediated immunity (75), exhibiting high specificity, tolerance to self tissues 
and immunological memory. Collectively, the two systems are complex, each 
composed of humoral factors and active specialised cells. However, they are 
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not independent but integrated and act together to combat infection (74, 76, 
77). 
1.2.3.1 Innate Immunity 
Innate immune response is the first line of defence for the human body, 
identifying foreign organisms within minutes of exposure (7, 76-78). The 
innate response is mediated by a number of cell types, such as phagocytes 
(leukocytes, macrophages, neutrophils and dendritic cells), eosinophils, 
basophils, mast cells and natural killer (NK) cells. All these cells are involved 
in phagocytosis, the killing of microbes and lysis of virus infected cells (77, 
79, 80). This system also activates the complement cascade, subsequently 
releasing proinflammatory cytokines and chemokines, which cause immune 
cells to rapidly move to the site of infection (65, 74, 77, 78). This non-specific 
process is not able to induce immunological memory within the innate cells, 
distinguishing them from the adaptive system (76, 77, 79, 81). 
 All these cells have sensors, located within the cell surface, endosomal 
membrane or cytoplasm, which detect structural motifs specific to pathogens, 
termed pathogen-associated molecular patterns (PAMPs). The sensors that 
recognise viral PAMPs are called pattern recognition receptors (PRRs) (78, 
80, 82). Viral PAMP examples include double-stranded RNA, single-stranded 
RNA, non-methylated CpG DNA and envelope glycoproteins (82).  
PRRs are made up of four families; two are membrane bound (toll-like 
receptors (TLR) and C-type lectin receptors (CLR)), and two are 
cytoplasmatic (nucleotide oligomerisation domain (NOD)-like receptors (NLR) 
and retinoic acid-inducible gene (RIG)- like receptors (RLR)) (74, 78) 
Detection of PAMPs and endogenous alarm signals (such as crystalline uric 
acid, heat shock proteins 60, 70, and 96, fragments of hyaluronan and 
fibronectin (78)) are necessary for the innate immune system to be activated. 
PAMPs are not expressed by vertebrates, which allows the host to 
differentiate itself from an invading organism (74). It has also recently been 
shown that PRRs identify endogenous damage-associated molecular 
patterns (DAMP), expressed when host tissue has been damaged (78).  
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The innate immune response is also mediated by the antigen presenting cells 
(APC) which include monophages, macrophages and DCs. These cells play 
an important role in the bridging of the innate and adaptive systems, by 
confining the threatening antigen, transporting and then presenting it to the 
adaptive lymphocytes. Originally it was thought that the innate system was a 
temporary, phylogenetic development of the immune response before the 
adaptive system was activated, but evidence now suggests that the innate 
immune response is often a requirement for the adaptive response to be 
triggered (74, 76, 79, 82). 
1.2.3.2 Innate Immunity in RSV Infection 
In the lung, factors such as pulmonary surfactant, act as part of the innate 
immune system to block viral infection including RSV. On infection the RSV-
induced immune response is characterised by interferon production and rapid 
inflammation within the airway, causing inflammatory cells to migrate from 
the bloodstream to the site of infection. Recruitment of these inflammatory 
cells, predominantly neutrophils, primarily results from chemokine expression 
following viral recognition by the innate immune system through pattern 
recognition receptors. Detrimental lung damage may be secondary to the up-
regulation of chemokine production, as well as damage by the virus itself  (1, 
15, 24, 36, 61).   
Pulmonary Surfactant 
Pulmonary surfactant consists of lipids (90%) and proteins (10%) and makes 
up a thin layer over the alveolar surface. Its role is to prevent alveolar 
collapse on expiration by decreasing surface tension. Both lipids and proteins 
interact with the proteins regulating lipids to maximise their role. In total there 
are four types of surfactant proteins (SP): A, B, C and D. The two hydrophilic 
proteins (SP-A and SP-D) are part of the C-type lectin family. C-type lectins 
are proteins involved with protection against invading viruses. Collectins, a 
family member, are vital soluble molecules in maintaining correct lung 
mechanisms and during the innate immune response (7).  
These surfactants have been shown to affect RSV pathogenesis and disease 
severity in both human and animal models, and are thought to be one of the 
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first lines of resistance within the lungs. Surfactant A attaches to the RSV F 
protein and encourages macrophage phagocytosis, whereas surfactant D 
inhibits RSV binding and neutralisation of RSV G protein (16). Lower levels of 
surfactants A and D have been found in the bronchoalveolar lavage of RSV 
positive patients (7, 16, 22, 65).  
Toll-like Receptors (TLRs) 
On infection PRRs, such as TLRs, play an important role in viral recognition. 
TLRs are highly evolutionally conserved within mammals. These type 1 
integral transmembrane glycoproteins are PRRs, which form part of the 
innate immune system and support the recognition of a variety of pathogen 
structures including viral nucleic acids. They are structurally characterised by 
leucine-rich repeat (LRR) motifs within the extracellular section. The LRR 
domain has an important role in ligand binding, and comprises 19-25 copies 
of repeated sequence consisting of 24-29 amino acids with the following 
residues; xLxxLxLxx (79). Once bound these receptors can trigger the 
immune response (79). 
A virus is recognised by TLRs expressed on the epithelium, activating a 
signalling pathway leading to the production of type I IFNs and transcription 
factors, such as nuclear factor kappa B (NF-ҡB), a regulator of pro-
inflammatory cytokine and chemokines expression (Figure 1.6) (16, 22, 83, 
84).   
In RSV infection, the RSV F protein has been shown to bind to TLR4 causing 
cytokine production (85, 86). Sensitivity towards endotoxins and other TLR4 
ligands has been suggested as a possible explanation for the link between 
RSV and inhaled allergen reactivity (16, 24). Rudd et al investigated the 
association between TLR3 and RSV (87). This group found that RSV-
induced chemokine release was mediated by TLR3. These experiments 
compared the response to RSV in lung epithelial cells expressing TLR3 to a 
negative control. CXCL8 and CCL5/RANTES (regulated on activation, normal 
T cell expressed, and presumably secreted) were significantly induced in the 
transfected cells 48 hours post RSV infection. TLR3 did not influence RSV 
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replication (87). Both TLR3 and TLR4 are expressed in the lung during and 
following infection (65). 
 
Figure 1-6: Toll-Like Receptor Signalling 
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This figure was kindly supplied by Dr. B Flanagan, and outlines the signalling 
pathway for toll-like receptors. TLRs expressed on the cell surface or within cell 
lysosome recognise pathogen associated molecular patterns (PAMPs). The 
extracellular structure of the TLRs are made up of LRRs. Co-receptors enhance 
TLR binding and signalling. For example, for TLR4 binding, MD-2 and CD14 are 
needed. The Toll/IL-1 receptor homologous region (TIR) adapter proteins 
become activated, thus continuing to activate the kinase proteins and then the 
transcription factors. NF-ҡB migrates to the nucleus, upon activation, for 
transcription of inflammatory genes. Interferon regulatory factors (IRF) initiate 
transcription for interferon genes. 
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Interferons (IFN) 
IFNs are a family of pleiotropic cytokines first described because of their 
ability to ‘interfere’ with or enhance resistance to viral replication (82). The 
importance of IFNs within the immune system has been demonstrated in 
murine models of infection, which shows that when IFN expression is 
reduced, pathogen spread is accelerated (16). 
There are two main types of IFNs. The type I IFN family can be expressed by 
most cells and include a number of highly related IFN-α forms, and one form 
of IFN-β. Expressed rapidly following viral infection of a cell, they are 
produced in response to PRR recognition of viral RNA or DNA. Type I IFNs 
act through a common cell surface receptor, the IFN receptor, widely 
expressed on most cell types and induce both autocrine and paracrine 
effects (82). Activation of a cell by IFN inhibits viral replication by increasing 
endonuclease expression which degrades viral nucleic acid and also 
decreases viral protein translation. Type I IFNs also up-regulate cellular 
major histocompatibility complex (MHC) class I expression, increasing the 
potential for cells to be recognised by cytotoxic lymphocytes. They also 
enhance NK cell activity and up-regulate expression of many proteins 
including inflammatory chemokines (3, 5, 6, 16, 82, 88-92).  
During early RSV infection type I IFN induction peaks, but soon declines as 
the infection progresses. As mentioned above, RSV NS1 and NS2 proteins 
act as type I IFN antagonists, with NS2 specifically interfering interferon 
induced activation of STAT2 (30, 67). 
Spann et al deleted NS1 and NS2 from the RSV genome, either individually 
or in combination, and showed a 40,000-fold increase in IFN-β mRNA 
expression when both proteins were deleted, compared to the control 
infected cells (93). The levels of IFN-β were found when both proteins were 
deleted together, deletion of NS1 only resulted in more IFN-β than deletion of 
NS2 alone, suggesting NS1 is the major inhibitor of IFN production (93). 
These results were quantified by antigen-capture enzyme-linked 
immunosorbent assay. These data suggest that IFN-α/β production is a very 
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early response to virus infection and inhibition of IFN production by RSV is a 
major mechanism to inhibit innate immunity (93, 94).  
In contrast, whilst it has strong antiviral effects, type II IFN (IFN-γ) is more 
closely related to adaptive immunity and produced by Th1, macrophages, 
NKT and NK cells (3). The full role of type II IFN production during RSV 
infection is still unclear. It has been shown that IFN-γ assists the cell-
mediated immune response against viral disease, and that there is an 
association between low levels of IFN-γ and severe RSV disease (3). 
Cormier et al investigated the role of IFN-γ in adult mice, and found that it 
was important in the eradication of RSV, but may also been responsible for 
tissue damage during the infection (26).  
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Figure 1-7: Interferon Signalling Pathway  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This image shows the interferon signalling pathway (82). 
The IFN-I is presented and binds to IFNAR-1 and -2 (interferon α/β receptor 1 and 
2), which activate the Jak1 and Tyk2 kinases. This results in the phosphorylation of 
STAT1 and STAT2 proteins. The IRF9 (interferon regulatory transcription factor 9) 
binds to these two proteins to produce the ISGF3 (Interferon-stimulated gene factor 
3) complex, which translocates to the nucleus and results in the transcription of 
ISGs. 
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Neutrophils, Macrophages and Eosinophils 
Neutrophils are the predominant leukocyte found in the airways of RSV 
infected children, making up 93% and 76% of the inflammatory cells within 
the upper and lower airway, respectively (65). 
In RSV infection, neutrophil chemotaxis is dependent on chemokine 
production, especially IL-8, released from airway epithelial cells and 
macrophages (65). It has been suggested that RSV delays adaptive 
immunity, perpetuating neutrophil recruitment, and consequently resulting in 
cell damage by disrupting, necrotic neutrophils (24, 65). In vivo, neutrophils 
are probably activated by a number of inflammatory signalling molecules, not 
just RSV (95). 
Alveolar macrophages express proinflammatory cytokines in response to 
RSV infection, such as TNF-α and IL-8 within the lower respiratory tract. 
They augment the innate response by encouraging vascular permeability and 
the migration of lymphocytes, neutrophils and natural killer (NK) cells towards 
infection. Later in RSV infection, macrophages hinder viral replication and 
have a role in the debris clearance reducing further inflammation and lung 
damage (96). In murine models, a lack of macrophages has also been shown 
to limit T cell activation and recruitment, suggesting a role in the immune 
response (16, 30, 65, 97). Sow et al investigated RSV susceptibility in 
preterm and full-term lambs (42). Their study, with a total of twenty lambs, 
showed that macrophage recruitment into the lungs was present in both 
groups following RSV infection. However, in the preterm lambs, 
macrophages differed in their activation process and being more immature. 
These responses may be relevant to disease pathogenesis in human infants 
born prematurely (42). 
Eosinophils have been reported to show antiviral activity. Elevated blood 
eosinophil cationic protein (ECP) is found in infants during recovery from 
RSV bronchiolitis compared to other acute illnesses, and is also associated 
with wheezing during RSV disease (6, 65). 
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Natural Killer (NK) Cells 
NK cells are innate immune lymphocytes capable of recognising viral infected 
cells by identifying abnormal cell surfaces secondary to the reduction of 
cellular MHC class 1 expression induced by some viruses (16, 76).    
NK cells can be activated by a number of cytokines, including IFN-β, IL-12 
and TNF-α, all found in the lungs of RSV-infected patients. They are the first 
subset of lymphocyte cells recruited to the lungs in RSV bronchiolitis.  
Between days 3 and 4 post RSV infection, NK cell recruitment from the blood 
to the lungs is at its highest in murine models (98). This is indirectly 
supported by the observation that blood NK cell levels are significantly lower 
in RSV infected children compared to controls (65). In RSV infection, there is 
debate about whether macrophages activate and recruit NK cells. Recent 
studies have shown that reduced number of macrophages can lower the 
number of activated NK cells (16, 26, 65, 76, 80). 
In primary RSV infection, invariant Natural Killer T (iNKT) cells, a subset of T 
cells that express characteristics of both NK and T cells, have been shown to 
release cytokines, especially IFN-γ, and to activate CD8 T cells (16, 82). 
Dendritic Cells (DCs) 
DCs are antigen-presenting cells that bridge the innate and adaptive immune 
responses. In response to a foreign antigen, organ-derived DCs are triggered 
and rapidly migrate to the regional lymph nodes taking with them antigens 
from the tissue. Once in the lymph nodes, DCs mature, increase expression 
of co-stimulatory molecules and regulatory cytokines, and present antigens to 
T cells. The immunological synapse, a membrane structure found within the 
interface between DCs and T cells, are critical for T cell activation. This 
activation process requires specialised molecular rearrangements between 
the DC and T cell surface, resulting in the polarisation of membrane-protein 
domains  (1). 
DCs capable of presenting RSV antigens are normally located beneath the 
respiratory epithelium. RSV has been shown to replicate within DCs and 
affect their overall function, particularly by inhibiting T cell activation with the 
lymph node (1).  
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Recent studies have suggested that this change in T cell activation could be 
due to RSV-induced expression of soluble and/or membrane bound 
molecules such as thymic stromal lymphopoietin (TSLP) (99). This molecule 
has an important role in the maturation of T cells and through its induction. 
RSV may affect the balance of Th1/Th2 cells, ultimately resulting in poor 
immunity and slow viral eradication 
Collectively, RSV can infect DCs, interfere with their development and impair 
their functional capacity to promote T cell activation (1, 74, 75, 79). 
1.2.3.3 Adaptive Immunity 
Adaptive immunity is highly specific and becomes evident several days 
following initial presentation of a foreign antigen. It can be divided into 
humoral and cellular components mediated collectively by B and T 
lymphocytes (79). 
1.2.3.4 Adaptive Immunity In RSV Infection 
Humoral Response 
The antibody response to RSV has primarily been studied in serum rather 
than the airway. Specific IgM levels increase initially at around five days post 
infection and remain elevated for several weeks post infection. IgG is 
produced subsequently around ten days post infection in serum and remains 
elevated for several months thereafter (65). Protective mucosal IgA has been 
shown to be elevated two to three days post-infection in adults (100). In 
acute RSV bronchiolitis, there is debate around the significance of serum IgE 
levels (65). 
The humoral response includes antibodies specific for each of the RSV 
proteins but viral neutralising antibodies are primarily against RSV F and G 
proteins (65). In murine models, Haynes et al found that anti-SP antibodies 
could initially reduce pulmonary inflammatory cell infiltration and the number 
of proinflammatory cytokines expressed, while anti-F antibodies lowered the 
virus titres (101). Lee et al investigated the levels of antibody-secreting cells 
(ASCs) in adult patients infected with RSV (102). 90% of the RSV infected 
patients had RSV F protein specific ASCs present within the first eleven days 
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of infection. No correlation was found between these RSV F specific ASCs 
and serum IgG response to RSV F protein, suggesting that serum IgG is a 
poor indicator of the response to RSV (102). 
The young age of many RSV bronchiolitis patients suggests that they should 
be protected by passive transfer of maternal immunoglobulins. Serum IgG 
levels varied between 180 and 656mg/dL in preterm infants born between 
24.5 and 35.5 weeks gestation (15). This is compared to 757 and 1100mg/dL 
in full-term healthy newborns at gestational age of 37 to 40 weeks (15). 
Serum IgG contains specific RSV neutralising antibodies, which should be 
present during the first six months of life. This coincides with the peak age for 
severe RSV bronchiolitis, causing debate on efficiency of these antibodies in 
supporting protective immunity. However it seems that children with higher 
titres of RSV neutralising antibodies are not as susceptible to the infection. 
Infants with low IgG levels (mostly preterm newborns) were at higher risk of 
developing RSV bronchiolitis and requiring hospitalisation, compared to 
infants with higher cord blood IgG levels. Furthermore, mothers of infants 
who did not become infected had higher maternal RSV specific IgG antibody 
levels, compared to mothers of infected babies (15). 
 Cell-Mediated Response 
There are a number of ways in which an impaired cell-mediated response 
may be important in RSV disease pathogenesis. DiNapoli investigated the 
effect that RSV has on the CD8+ CTL (cytotoxic T lymphocyte) response 
within the lungs. In RSV-infected mice models, CD8+ CTLs are impaired 
characterised by the low expression of IFN-γ, a measure of functionality. This 
impairment was thought to reduce the host's immune response and thus 
explain the ability RSV has to re-infect throughout life (103). 
Other impairments in the cell-mediated response are, firstly, thought to be 
due to immaturity of the immune response, as the patients are usually very 
young. Secondly, RSV infection could permanently modify the antibody and T 
cell response. Viral clearance relies on the maintenance of a balanced Th1/2 
response, as this stimulates the release of neutralising antibodies and 
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cytotoxic CD8+ T cells. It is thought this response can become imbalanced, 
so that the mechanism does not work successfully (1, 6, 15, 65, 79).  
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Figure 1-8: Lymphocyte Differentiation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This image was kindly supplied by Dr. B Flanagan. It shows the stages of T cell 
differentiation into the four main types, and cytokines that they express. The main 
function/s of each type are also labelled at the bottom. The abbreviations are as 
follows: TH1, T helper cell 1; TH2, T helper cell 2; TH17, T helper cell 17; Treg, 
Regulatory T cell; DC, Dendritic cells; Ker, Keratinocytes; Epit, Epithelial cells; B, 
Basophils; Eos, Eosinophils; Mast, Mast cells; Fib, Fibroblasts; Epit, Epithelial cells; 
and Neut, Neutrophils. 
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T Helper Responses 
There are four main types of helper T cells: Th1, Th2, Th17 and T regulatory 
(regs) (Figure 1.8). 
In response to a pathogen, Th1 and Th2 cells release IFN-γ, IL2, TNF-α and 
IL-4, IL-5, IL-10, IL-13, respectively (65). There is much debate about which 
Th cell has the most involvement in response to RSV, but no extensive study 
of the response by T regulatory or Th17 cells has been published. Most 
reports focus on a potential bias towards Th1 or Th2 cell production in 
humans. The first description of a Th1/2 polarisation came from murine 
models. Vaccinating BALB/c mice with a recombinant virus primarily 
expressing the RSV F protein, results in Th1 and CD8+ cytotoxic lymphocyte 
activity (16). However, infecting mice with recombinant virus expressing the 
RSV G protein, results in Th2 cytokine release and eosinophilia (65).  
This work, and the clinical similarities between bronchiolitis and the prototypic 
Th2 condition asthma, led to multiple studies trying to identify a Th2 response 
in human infants with RSV bronchiolitis (30). 
Positive correlations are seen in the nasal lavage fluids between infants 
suffering from acute RSV bronchiolitis and elevated IL-4 and IL-5 expression, 
compared to infants with URTI alone, emphasising possible Th2 involvement 
within the disease (30, 104). Some studies showed that more IL-4 is present 
in BAL samples of RSV infected children than IFN-γ. Other studies showed 
that lung and tissue injury were more likely in the presence of Th2 
polarisation during a second exposure of RSV infection. Collins et al also 
reviewed other studies showing Th1 bias and Th1 and 2 responses to the 
virus, thus concluding that Th2 is likely to play a role in the 
immunopathogenesis of RSV infection, but may not be the dominant Th 
lymphocyte response (30). In a separate study evidence for a Th1 response 
was seen in nasopharyngeal secretions from RSV infected patients, which 
showed increased levels of IFN-γ (1, 16, 26, 30, 65).  
Cytotoxic Lymphocytes 
In murine studies, CD8+ T cells are found to be elevated within the lungs and 
surrounding tissues during RSV infection. Increased numbers of RSV specific 
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CD8+ cytotoxic lymphocytes have shown to be associated with improved 
viral clearance. This suggests that an inadequate T cell response to RSV 
could contribute to a poor memory immune response, subsequently 
promoting reinfection (1, 16, 26, 30).  
Approximately 80% of infants suffering from RSV bronchiolitis had RSV-
specific cytotoxic lymphocytes present within the lungs. These cells have a 
short half life, thought to be due to them being preserved in preparation for a 
second exposure of the virus. Older infants appear to have higher 
concentrations of T cells, which again may be secondary to immune 
immaturity in younger infants. RSV specific CD8+ T cells positively correlate 
with IFN-γ levels, and inversely with IL-4 levels. Subsequently, if a T cell 
response is present before an infant is one year old, then they have a 
significantly reduced chance of obtaining severe disease in their second 
exposure to the virus (65). 
Oshansky et al compared RSV specific CD8+ T cells isolated in the lungs and 
spleen in their ability to release IFN-γ (16). CD8+ T cells were less able to 
release IFN-γ in the lung environment, and were not affected by other factors 
such as virus type, viral antigen and infection course (16). 
1.3 RNA Interference 
In October 2006, the Nobel Prize for Physiology and Medicine was awarded 
to Drs. Andrew Fire and Craig Mello for work originally published in 1998. 
The Nobel Prize was for the discovery of RNA interference (RNAi), where 
gene expression is inhibited by interfering with its transcription and 
translation. They inserted long double-stranded RNA (dsRNA) into 
Caenorhabditis elegans, which resulted in the silencing or "knockdown" of a 
specific protein with the corresponding mRNA sequence. In 2001, it was 
discovered that RNA interference also happens within human and other 
mammalian cells.  
Around this time, the concept of small-interfering RNAs (siRNA) was also 
introduced. These short and specific dsRNA are approximately 21 to 23 base 
pairs long (Figure 1.9). They are produced from long dsRNA by a Dicer (an 
RNase) and have a distinctive layout, with a single-stranded 2-nucleotide 
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long 3’ overhang at both ends. They are able to continue the interference 
function with their complementary, antisense strand to the target mRNA, 
thus, producing a substance that specifically silences a gene function, 
without modifying the gene itself (2, 105-111).  
 
Figure 1-9: Structure of siRNA 
 
The structure of the siRNA is specific for complementary binding within RISC (82). 
The siRNA complex is made up of 21 nucleotides, a 19 base pair section of duplex 
and two overhanging nucleotides on the 3' end of each strand. 
 
There are two separate processes for generating RNAi (Figure 1.10): siRNA 
and microRNA pathways. Both silence protein function, but the siRNA 
process occurs mainly in the cytoplasm of the cell, whereas the microRNA 
process occurs within the cell’s nucleus. In the siRNA pathway, the specific, 
complementary siRNA becomes incorporated into the RNAi-induced 
silencing complex (RISC) and the sense strand is cleaved off, leaving the 
antisense strand in the RISC. This siRNA antisense strand is able to 
recognise the target sequences of cytoplasmic mRNA and direct the RISC for 
mRNA target cleavage (82). The siRNA process is more commonly used in 
the study of human therapeutics (105, 106). 
The impact of the discovery of RNAi has been profound as a research 
technique, increasing our understanding of the pathogenesis of multiple 
conditions. However, its great application may not yet have been realised, 
given its obvious therapeutic potential. 
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Figure 1-10: SiRNA (and microRNA) pathway 
 
 
This shows the two pathways (siRNA and microRNA) of RNA interference (82). The 
siRNA pathway is focused on, due to the use of synthetic siRNA in this project. 
Therefore. the initial step of dsRNA cleavage by the Dicer enzyme into specific 
siRNA does not occur. This complementary siRNA attaches to the AGO2 (an 
associated protein) in the RISC, which cleaves the sense strand, leaving the 
antisense strand in RISC. This antisense strand directs the RISC and AGO2 
towards target sequences of cytoplasmic mRNA for cleavage and thus, results in 
reduced translation of the encoded protein. 
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1.4 Innate Resistance Genes 
Much of this thesis is based on studies initiated by Prof. Ralph Tripp in 
Atlanta at University of Georgia. He has used high throughput screening to 
investigate which genes regulate influenza replication, by knocking down the 
expression of host genes in airway epithelial cells using siRNA. He has 
provided the Alder hey RSV group with a list of 26 genes which, when 
knocked down, caused increased influenza replication in airway epithelial 
cells.  
Table 1.1 shows the names and details of these genes. For most of them, 
little published information is available.  
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Table 1-1: Name and details of E3 subset ubiquitin ligases 
Gene/Protein Information 
Kinase Family 
 
Mitogen Activated Kinase Kinase 
Kinase 1 (MAP3K1)  (112) 
 
Found on chromosome 5.  
Serine/Threonine Kinase. Signal transduction. 
Activated by phosphorylation pathway and 
requires Mg2+ before it can phosphorylate other 
proteins. 
Phosphatase Family 
 
Protein Phosphatase, Mg2+/Mn2+  
Dependent, 1H (PPM1H)  (112) 
 
Found on chromosome 12. 
Member of PP2C phosphatase family. 
Involved in signal transduction. 
G-Protein Coupled Receptor Family 
 
G Protein-Coupled Receptor 34 
(GPR34)  (112-115) 
 
Found on X chromosome. Membrane protein. 
Orphan receptor in rhodopsin-like subset of 
GPCR family. 
Triggers intracellular signals through the 
stimulation of heterotrimeric G proteins.  
No interactions associated with this protein 
found. 
Histamine Receptor H2 (HRH2)  
(112) 
Found on chromosome 5. 
Maintains efficient cell growth and 
development.  
HRH4  (112) Found on chromosome 18. 
Role in inflammation and allergic reactions. 
Chemokine (C-C motif) Receptor 
7 (CCR7)  (116, 117) 
 
 
Found on chromosome 17 and located on 
surfaces of B cells, T cells and DCs. Activated 
by two ligands: CCL19 and CCL21. 
Role: migration of immune cells to lymph 
nodes and development of DCs. 
RSV-infected CCR7-deficient mice suffered 
more severe disease, with impaired migration 
of immune cells and reduced T cell responses. 
Chemokine (C-X-C motif) 
Receptor 3 (CXCR3)  (118) 
 
Found on chromosome X and binds to CXCL9, 
CXCL10 and CXCL11.  
Leukocyte trafficking and T cell polarisation. 
Chemokine (C-X3-C motif) 
Receptor 1 (CX3CR1)  (112) 
Found on chromosome 3. 
Unique receptor for chemokine fractalkine 
(CX3CL1).  
Ability to bind with RSV G gylcoprotein. 
E3 Subset Ubiquitin Ligases 
 
Ring Finger Protein (RNF) 149 
and RNF150  (112) 
Found on chromosome 2  and 4, respectively. 
Roles in protein and zinc binding. 
RNF168  (119-121) Found on chromosome 3. 
DNA damage ubiquitin ligase via post-
translational modifications and contributes to 
K63-polyubiquitin chains. 
Chromatin binding by inducing ubiquitinylation 
of histones. 
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Membrane-Associated Ring 
Finger (C3HC4) 6 (MARCH6)  
(112) 
Found on chromosome 5 and confined to the 
endoplasmic reticulum. 
CCR4-NOT Transcription 
Complex, Subunit4 (CNOT4)  
(112, 122) 
 
Found on chromosome 7. 
E3 ubiquitin ligase, containing RING finger 
domain and 78 N terminal residues essential 
for interaction with E2 ligase, UBE2D1. 
Pairing induces protein recognition and 
ubiquitinylation. 
Positively up-regulates IFN-γ and IL-4, which 
stimulates JAK/STAT pathway. 
Polycomb Group Finger 5 
(PCGF5)  (112) 
Found on chromosome 10. 
Role in protein and zinc ion binding. 
PHD Finger protein 21A 
(PHF21A)  (112) 
Found on chromosome 11 
Bind to number of molecules, such as DNA, 
chromatin and proteins. 
Suggested roles in RNA transcription 
prevention, blood coagulation and chromatin 
modification. 
RAD18 Homolog  (112, 123, 124)  
Geng , Williams 
Found on chromosome 3. 
Role in post-replication repair of damaged 
DNA and regulates ubiquitinylation and 
chromatin binding. 
RUN and FYVE Domain 
Containing 1 (RUFY1)  (112, 125) 
 
Found on chromosome 5 and initially in 
endosomes. 
Structure: N-terminal RUN domain and C-
terminal FYVE zinc finger domain, connected 
by two coiled-coil domains. 
Suggested role in endocytosis. 
Topoisomerase I Binding, 
Arginine/Serine Rich (TOPORS)  
(112, 126) 
 
Found on chromosome 9. 
Nuclear protein rich in arginine and serine, 
consisting of RING-type zinc finger domain. 
Role: tumour suppressor 
Ring Finger and FYVE-like 
domain containing 1 (RFFL or 
Rififylin)  (112, 127) 
 
Found on chromosome 17. 
FYVE-like domain (N-terminal); RING finger 
(C-terminal). 
Zinc and protein binding. 
TRIM 2  (112) 
*Details about TRIM family 
below* 
Found on chromosome 4 within cytoplasmic 
filaments. Contains both B-box motifs. 
TRIM 15 (112) 
 
Found on chromosome 6 within cellular 
cytoplasm. Contains both B-box motifs. 
TRIM 37  (112) Found on chromosome 17 and contains one B-
box motif. 
Function: genetic mutations and oncogenesis. 
TRIM 43  (112) 
 
Found on chromosome 2. 
Contains common C-terminus SPRY domain. 
TRIM 73  (112) Found on chromosome 7. 
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These 26 'innate resistant genes' can be grouped into four families: Kinases 
(1 gene), Phosphatase (1 gene), G Protein Coupled receptors (6 genes) and 
Ubiquitin E3 Ligases (18 genes). These families are described below, along 
with a few of the genes where more published information is available. 
1.4.1  Kinase Family 
The kinase cascade signals in response to extracellular stimuli and 
compromises mitogen activated protein (MAP) kinase (MAPK), MAP kinase 
kinase (MAP2K) and MAP kinase kinase kinase (MAP3K). The activated 
cascade is involved in a number of cellular activities, such as cell growth, 
migration, proliferation, differentiation, apoptosis and signal transduction, and 
is regulated through a phosphorylation pathway from MAP3K to MAP2K to 
MAPK. In total there are 13 members of the MAPK family, with the first being 
discovered in the 1980s (128-131).  
The only kinase identified by Prof Tripp was MAP3K1. This serine/ threonine 
kinase is located on chromosome 5 and is important in the signal 
transduction cascade that involves ERK and JNK pathways. It is triggered by 
the phosphorylation pathway, and requires Mg2+ before it can phosphorylate 
any other proteins (112). 
1.4.2  Phosphatase Family 
Protein phosphorylation and de-phosphorylation of both the kinase and 
phosphatase families is pivotal for normal cell function and signal 
transduction (132). Phosphates can block the phosphorylation relay between 
MAP3K and MAP2K, and thus, have the power to alter the MAPK activity 
regulating cell proliferation, survival or apoptosis (131, 133).  
In total there are three main Phosphatase groups: 1) the Phosphoprotein 
phosphatase (PPP) superfamily (including PP1, PP2A and PP2B families); 2) 
the Transcription factor II F (TFIIF) superfamily; and 3) the Protein 
phosphatase magnesium (Mg2+) and/or Manganese (Mn2+)-dependent (PPM) 
superfamily (including PP2C family) (131). This last superfamily contains one 
of the proteins identified in Atlanta (PPM1H). 
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PPM1H is a member of the PP2C phosphatase family located on 
chromosome 12. There is no published data about PPM1H in association 
with infection. Also, no interactions have been found between PPM1H and 
other structures. From the information above, we can infer that PPM1H must 
be involved with the MAPK cascade, influencing cell functions and signal 
transduction (112).  
1.4.3  G Protein Coupled Receptor (GPCR) Family 
GPCRs are the largest and most diverse cell-surface protein superfamily, 
with at least 1% of the mammalian genomes encoding this receptor group. 
There are approximately 900 genes that programme for GPCRs in humans, 
including 400 that are specific olfactory receptors. They are an impressive 
group of cellular signal transducing proteins, whose role, as their name 
implies, is to transfer information about a physical entity across cells to 
stimulate a response. Their ability to mediate messages from a broad range 
of ligands (including ions, hormones, neurotransmitters, odorants, lipids, 
proteins and even photons) is a key feature of this family. This ability means 
that these receptors play a role in external (e.g. photons inducing sight) and 
internal (peptides inducing neurological effects) processes. Due to their 
specificity, GPCRs are a popular choice for drug development research (134, 
135).  
They are also known as, seven transmembrane receptors, because of their 
common structure; a central core domain consisting of seven 
transmembrane-spanning hydrophobic α-helices. This complex contains 25-
35 amino acid residues each with three intracellular and three extracellular 
hydrophilic loops. The intracellular C-terminal region participates in G-protein 
linking and phosphorylation, whereas the extracellular N-terminal region is 
important in chemokine binding. These chemokine GPCRs can stimulate a 
number of processes, such as JAK, STAT and MAPK pathways (113, 136-
138).  
GPCRs in vertebrates are classified into 5 groups: 
1. Family A – Rhodopsin- like. This is the largest and most ancient of the 
five subsets. It is further divided into P2Y12-like receptor group, 
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including ADP receptor P2Y12 and P2Y13, and the UDP-glucose 
receptor P2Y14, and orphan receptors – GPR34, GPR38 and GPR87. 
2. Family B – Secretin - like. 
3. Family C – Glutamate – like. 
4. Family D – Adhesion. 
5. Family E – Frizzled/Taste2. 
Unfortunately, “orphan” GPCRs, whose structures are similar to other 
GPCRs but with unknown agonists, do not fit into any of the categories, apart 
from the above three (114, 115, 135, 139).  
Prof. Tripp's group identified six members of the GPCR family as being 
important in influenza replication. 
These include two histamine receptors (HRH2 and HRH4) that are expressed 
on mast cells, enterochromaffin-like cells and neurons. They have similar 
functions, primarily as signal transducers. As their names suggest, they play 
a role in activating cells in the presence of histamine, an active amine 
produced in allergic reactions. HRH4 has a regulation role in the innate 
immune response, causing chemotaxis of a number of innate cells, such as 
eosinophils, mast cells and DCs. It is known to interact with one molecule – 
IRF8, one of a family of proteins that regulate IFN genes. Its only known 
relationship with respiratory disease is the release of HRH4 into the airways 
in asthma, with HRH4 antagonists suggesting that they may reduce levels of 
eosinophils within the lungs and Th2 responses (112, 140, 141).  
For CXCR3 most research has focused on its interaction with CXCL10. Roe 
et al discovered that during RSV bronchiolitis, the levels of CXCR3 positive 
Th1 lymphocytes are considerably lower in blood (142). This decrease was 
thought to be secondary to elevated CXCL10 levels, with all the levels 
returning back to normal three months post infection. McNamara et al found 
elevated CXCL10 levels in the lungs of RSV infected infants, supporting this 
idea (65). Roe suggests that the migration of Th1 lymphocytes towards the 
lungs during RSV infection might account for the low blood levels (142). 
Another suggestion from Roe is that Th1 lymphocyte death may result in 
increased CXCL10 levels (65, 142).  
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CX3CR1 is the unique receptor for the chemokine fractalkine (CX3CL1), the 
only member of the CX3C motif chemokine family (143). Fractalkine is a 
large, membrane-bound glycoprotein core connected via a mucin stalk to a 
COOH-terminal transmembrane segment (144). It can be found in soluble or 
membrane-bound forms and acts as either a leukocyte chemoattractant or 
cellular adhesion substrate (143, 145, 146). Fractalkine is released by human 
epithelial cells in reply to the proinflammatory response (TNF-α and IL-1) and 
results in migration of CX3CR1-expressing cells (monocytes, NK cells and T 
lymphocytes) (147-149). Tripp et al discovered that RSV G glycoprotein has 
a similar structure to fractalkine, and also has the ability to bind to CX3CR1 
(150). This glycoprotein contains the CX3C motif on amino acids 182 to 186 
and no other chemokine motif (145, 146, 148, 149, 151). Both fractalkine and 
G protein are large glycoproteins with intracellular, transmembrane and 
extracellular sections, with both secreting and membrane-bound structures. 
They both have heparin-binding domains that can attach to 
glycoaminoglycans (GAGs) on cell membranes. When the G protein binds 
CX3CR1, two responses are seen (150). Firstly, leukocyte migration and 
secondly viral clearance is reduced. These data suggest that RSV G protein 
and fractalkine compete for CX3CR1 binding (146, 149, 152).  
1.4.4   E3 Subset Ubiquitin Ligase 
Ubiquitinylation is a process that determines the post-translational fate of a 
protein (153). As well as protein turnover, ubiquitylation is important in cell 
cycle development, DNA repair and signal transduction. It is thought that 
viruses are able to affect this pathway, and recent data has shown that viral 
entry into cells is blocked when ubiquitinylation is blocked (154).  
Ubiquitylation involves the movement of ubiquitin, a stable 76 amino acid 
protein, through an enzyme cascade to produce an isopeptide bond between 
the ubiquitin and a lysine on a target protein (153). This bond is attached via 
the C-terminus of the ubiquitin and the ϵ-amino group of the lysine. The 
following three enzymes comprise the enzyme cascade (Figure 1.11): 
ubiquitin-activating enzyme (E1), ubiquitin-conjugating enzyme (E2) and 
ubiquitin ligase enzyme (E3). Most of the 'innate resistance genes' identified 
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by Prof. Tripp were E3 ubiquitin ligases, which contain a RING (Really 
Interesting New Gene) domain. E3 ligases bridge the gap for the transfer of 
the ubiquitin from the E2 site to the substrate. The RING-type E3 binds to E2 
without modifying the structure and binds to the site furthest from E2’s active 
site. This attachment is specific and initiates the chain development on the 
lysine.  
So far, over 650 human RING-type E3 ligases have been discovered. 
Viswanathan has found that RSV can degrade STAT2 via the E3 ligase 
complex (121, 153-156). 18 E3 ligases in total have been identified by Prof. 
Tripp. This includes five members from the TRIM family (Section 1.4.4.1). 
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Figure 1-11: Ubiquitin Proteosome System 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This figure describes protein degradation via the ubiquitin-proteasome pathway 
(157). 1) Ubiquitin attachment to target protein substrate via a covalent bond 
requires three enzymes. E1, ubiquitiin-activating enzyme, activates and binds to the 
C-terminus residue of ubiquitin. Activated ubiquitin is transferred to ubiquitin 
conjugating enzyme, E2, and then to the ubiquitin-protein ligase,E3, where it is 
attached to the target protein. A covalent bond is formed between the ubiquitin and 
ϵ-amino group of lysine residues within target protein. 2) 26S proteasome complex 
is made up of 20S catalytic core and two 19S regulatory complexes. It degrades the 
tagged proteins, resulting in the release of recycled ubiquitins by deubiquitinating 
enzymes (DUBs). 
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1.4.4.1 Tripartite-Motif Protein (TRIM) Family 
Five members of the TRIM superfamily have been identified by Prof. Tripp. 
This superfamily, a subset of the ubiquitin E3 ligase family, is made up of 
over 70 members (158) who encode proteins involved in a number of 
biological processes, and are mainly found in both the cell cytosol and 
nucleus (159). Each member consists of the same specific tripartite motif: 
RING domain, one or two B-box motifs and a Coiled-coil region. Because of 
this structure, TRIM members can also be called RBCC proteins (160). 
RING domain: a zinc-finger binding motif located on the N terminus of the 
TRIM members, within 10-20 amino acids of the initial methionine. As 
mentioned above, it is an important component in E3 ubiquitin ligases and 
thus is involved in ubiquitylation and protein-protein interactions (161). 
B-box motifs: are cysteine-rich zinc-binding domains. Either 1 or 2 B-box 
motifs are present in the TRIM member. If both B-box motifs are present then 
B-box 1 always comes before B-box 2, whereas if only on B-box motif is 
present then this will always be motif 2. These are unique to the TRIM family 
and are important in viral replication (161). Uchil et al investigated the 
absence of the B-box in TRIM15, and found that it caused the disappearance 
of its antiviral state (158). 
Coiled-coil domain: is made up of a number of α-helices, which mediates 
homomeric and heteromeric interactions. They are present in a number of 
proteins and are particular important in self-association (160).  
The classification for the TRIM family is determined by the C-terminus, which 
was discovered by Short and Cox. There are ten individual motifs, making up 
nine families – CI to CIX. Two separate groups have since been added; CX 
which contains TRIM45 and CXI for TRIM13 and TRIM59 as they do not fit 
into the other groups. The most common C-terminals are: PRY domain with 
approximately 61 amino acids and SPRY which consists of around 140 
amino acids (161). 
In recent data, it has been discovered that TRIMs have a role in innate 
immunity. As mentioned above IFN-I programmes the antiviral state and from 
this data has shown that IFN-I can up-regulate a number of TRIMs in 
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response to a viral infection (162). The TRIMs ability to inhibit the entry of the 
virus, transcription and spread means research has begun to focus on its role 
in immune signalling and antiviral environment (158-160, 162-164)  
1.5 Aims and Objectives 
This MPhil thesis is a continuation of the work undertaken by Professor R. 
Tripp who provided the Alder Hey RSV group with a list of innate resistance 
genes that when knocked down by siRNA, increased influenza replication in 
airway epithelial cells 
 
The aim of my work over this past year has been: 
 To determine whether I could ‘knockdown’ the expression these 
twenty-six genes in airway epithelial cells using a similar siRNA 
protocol to that used by Prof. Tripp. 
 To determine which genes provide protection against both influenza 
and RSV, by infecting ‘knockdown’ cultured epithelial cells with RSV, 
and measuring viral replication and RSV N gene expression. 
 To further investigate the significance of these results by focusing on 
some of these genes in more detail. 
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2  Materials and Methodology 
2.1 Cell Culture 
A549 cells (a type II pulmonary epithelial cell line) were grown in Dulbecco’s 
Modified Eagles Medium (DMEM, Sigma). Medium was supplemented with 
10% Foetal Calf Serum (FCS, Sigma), L-glutamine 200mM (Sigma), 
Penicillin 10,000units/ml (Sigma) and Streptomycin 10mg/ml (Sigma). 
The cells were sub-cultured two to three times a week at a concentration of 
106 cells/ml of fresh media in T75 flasks, incubated at 37oC with 5% carbon 
dioxide.  
2.1.1  Seeding A549 cells 
Stock A549 cells were cultured as above and in each experiment seeded as 
follows: 
Media was removed from a T75 flask of cells, which were washed once with 
10ml of Phosphate Bovine Saline (PBS). 5ml of 0.25% trypsin 0.02% EDTA 
(Sigma) was then added and the flask was incubated at 37oC for two 
minutes. The flask was then tapped to dislodge cells from the base of the 
flask. 10ml of FCS supplemented media was then added (L-glut, Strep + 
Pen) to neutralise and deactivate the trypsin. Cells were then centrifuged at 
700 x g in room temperature for ten minutes, and the supernatant removed. 
The pellet was resuspended in 5ml of media and the number of cells counted 
using a haemocytometer. Depending on how many cells were needed, cells 
were diluted with DMEM plus 10% FCS and pipetted into each well or flask.  
2.2 RSV Preparation 
2.2.1  RSV Propagation  
Although I did not prepare all the RSV stocks over the year, the same 
method of preparation was used for each batch.  
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Day One: 
Hep2 cells were seeded at 30,000 cells/cm2 in a total volume of 15ml of 
DMEM plus 10% FCS, in a T75 flask, and grown for 24 hours at 37oC in 5% 
CO2 until 50% confluent. 
Day Two 
Medium was removed from cells at 50% confluence, and cells washed twice 
with PBS. 500μl of an RSV A2 stock was placed in 4ml of FCS-free medium 
and added to the flask of cells. To ensure the stock spread over the whole 
flask they were rocked gently for two hours at 37oC. 
13ml of medium (+ 2% FCS) was then added and the flask left overnight in 
the incubator. 
Day Three 
The media was changed to ensure that both cells and virus had enough 
nutrients and the flask was again incubated overnight at 37oC. 
Day Four 
Usually 48 hours post infection, infected cells from cultures showing visible 
signs of cell death and detachment were harvested using a cell scraper. To 
ensure virus integrity, the following steps were carried out rapidly and cells 
kept on ice so that the RSV did not begin to degrade. The harvested cells 
were placed into a 50ml tube and spun down at 1500rpm for 5mins at 4oC. 
Supernatants were removed into a separate tube on ice and the pellet 
resuspended in 2ml of the removed supernatant and mixed thoroughly, 
before removing 1 ml into two microcentrifuge tubes on ice. The cells were 
lysed using a 25gauge needle and 1ml syringe for ten passes on ice. This 
caused the Hep2 cells to burst open and release RSV. Promptly, 500μl was 
transferred to four pre-labelled cryovials and snap froze in liquid nitrogen. 
Vials were ultimately stored at -70oC. 
2.2.2  RSV Plaque Assay 
The PFU per ml for each batch of RSV was measured using the following 
protocol. 
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Day One: 
2 x 104 A549 cells per well were seeded into a flat bottomed 96 well plate. In 
total, 27 wells (9x3) were used per batch of RSV, which was grown in DMEM, 
supplemented with 10% FCS, L-glutamine, penicillin and streptomycin, at 
37oC for 48 hours. 
Day Three: 
Eight two-fold serial dilutions of RSV stock to be titred were prepared as 
follows. 500μl of FCS-free DMEM was placed into the first tube and 250μl in 
seven further tubes, each prepared on ice to prevent the RSV from 
degrading. RSV was removed from the -70oC and snap thawed using a water 
bath at 37oC. 5μl of this RSV was then added to the first tube and mixed well, 
dilution 1:100. 250μl was then transferred from the first tube to the second 
and doubling dilutions prepared until the eighth tube.  
A549 cells were then washed with PBS and 50μl of the above dilutions, 
added to wells in triplicate going horizontally along the plate. The plate was 
then left in the incubator at 37oC for two hours. Then 100μl of supplemented 
DMEM (with FCS) was added to each well and the plate incubated overnight 
at 37oC.  
Day Four: 
Cells were first washed with 100μl PBS per well and then fixed with 100% 
methanol containing 2% hydrogen peroxide (100μl/well) at room temperature 
for 20 minutes. Cells were again washed with 100μl PBS, carefully avoiding 
disruption to the monolayer using a multi channel pipette. Care was taken to 
avoid ejecting PBS directly onto the monolayer.  
After 20 minutes, 100μl of biotinylated Goat anti-RSV antibody (Serotec), 
diluted 1/200 with PBS and 1% Bovine Serum Albumin (BSA), was added to 
each well and the plate incubated for one hour at room temperature. 
Cells were then washed twice (100μl/well) with PBS/1% BSA, before 100μl of 
extravidin peroxidase (2mg/ml; Sigma-Aldrich) diluted 1:500 with PBS was 
added to each well and then left for 30 minutes at room temperature. 
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Cells were washed twice again with 100μl PBS/1% BSA prior to 50μl of a 
solution prepared using one Sigma-Fast Red Tablet diluted in 5mls of PBS, 
being added to each well for stain development. This was left for 
approximately ten minutes, or until the plaques appeared. The reaction was 
stopped by addition of PBS and plaques counted. The dilution that produced 
around 100 – 200 plaques per well was selected and each replicate counted 
to gain an average value. Dilutions above and below this one were also 
counted to limit error. The RSV plaques have been shown in Figure 2.1. 
The plaque forming units per ml was calculated using the formula: 
Number of plaques x dilution (e.g. 100, 200, 400 etc) x 20. 
The dilution for each well was as follows: 
Dilution 1 = 1/100 
Dilution 2 = 1/200 
Dilution 3 = 1/400 
Dilution 4 = 1/800 
Dilution 5 = 1/1600 
Dilution 6 = 1/3200 
Dilution 7 = 1/6400 
Dilution 8 = 1/12800 
 
The Multiplicity of Infection (MOI) used in experiments was calculated, as 
was the ratio between the number of RSV particles and the number of target 
cells within a specific area or sample. This was calculated by dividing the 
RSV particles over the known cell number.    
Figure 2-1: RSV plaques 
formed during the plaque 
assay protocol. 
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2.2.3  RSV Infection 
A549 cells were seeded into the correct sized plates or flasks as described in 
Section 2.2.1.  After 48 hours of incubation at 37oC, the cells were 90% 
confluent and ready to be infected. The cells were washed once with PBS 
prior to infection. Stock RSV was snap thawed using a water bath at 37oC 
quickly to avoid virus degradation. Depending on the dilution and volume 
required, the specific amount of RSV was mixed with FCS-free media and 
placed onto the cells.  
The cells were left to incubate at 37oC again for two hours, before 
supplemented (+FCS) media was added. Following infection, cells were left 
for either 24 or 48 hours depending on the experiment being undertaken. 
2.3 RNA Extraction and Isolation  
The extraction and isolation of RNA methodology is as described by the 
manufacturers of TRIzol® reagent, Invitrogen. 
2.3.1  Homogenising Sample 
Culture supernatants were removed from the cells and stored at -20oC for 
future experiments. The samples were then homogenised by TRIzol® 
reagent (Invitrogen), which isolates good quality RNA from the A549 cells. 
TRIzol® is a monophasic solution made up of phenol and guanidine 
isothiocyanate. TRIzol® reagent can be a health hazard and must be used in 
a fume cupboard and then neutralised with 1% sodium hydroxide before 
being disposed of.  
0.75ml of TRIzol® was used per 0.25ml of sample containing 5-10x106 cells. 
Insufficient volumes would have caused DNA contamination within the 
isolated RNA. It was important not to wash the cells before using the TRIzol® 
because it would have increased the possibility of degradation of the mRNA. 
The sample was pipetted up and down a number of times to ensure all the 
cells were in the TRIzol® solution. Each sample was then placed into 
individual tubes. 
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2.3.2  Phase Separation 
The homogenised sample was then incubated at room temperature for five 
minutes to ensure complete dissociation of nucleoprotein complexes had 
occurred. Next, 0.2ml of chloroform per 1ml of TRIzol® initially used was 
added to each sample, followed by a vortex for fifteen seconds to be sure 
that they were thoroughly mixed. The samples were then incubated for two 
minutes at room temperature before being centrifuged at 12,000 xg for ten 
minutes. After this, the sample separated into three different layers: 1) lower 
red phenol-chloroform phase; 2) interphase; 3) colourless upper aqueous 
phase, which makes up approximately 50% of the volume and is where the 
RNA was located. 
The aqueous layer was removed carefully by angling the tube to 45o and 
pipetting the clear layer. It was important to only get the one layer to prevent 
DNA contamination. This solution was then placed into a new and clean tube. 
2.3.3  RNA Precipitation 
0.5ml of 100% isopropanol per 1ml of TRIzol® used was added to each 
sample before being vortexed for fifteen seconds. The samples were then 
placed into the -20oC freezer for 30 minutes. At this point the RNA was 
normally invisible, but after freezing, the samples were centrifuged at 12,000 
xg for fifteen minutes. This resulted in a gel-like pellet forming on the side 
and bottom of each tube. 
2.3.4  RNA Wash 
The pellet was then washed with 1ml of 75% ethanol per 1ml of TRIzol® 
used and kept in ethanol for storage. When needed, this solution was 
centrifuged at 7500 xg for five minutes and the ethanol removed. The pellet 
was then air dried for approximately five to ten minutes and once dry, 10μl of 
sterile, nuclease- free water added to the pellet. 
2.3.5  Reverse Transcriptase 
cDNA (complementary DNA) for template real-time PCR to take place was 
prepared using a High Capacity cDNA Reverse Transcription Kit (Applied 
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Biosystems). This supports cDNA synthesis using the random primer 
scheme. The following components were added to each mRNA sample to be 
reverse transcribed: 
1. 10X RT Buffer     2μl/tube 
2. 25X dNTP Mix (100mM)   1μl/tube 
3. 10X RT Random Primers   2μl/tube 
These components and 4μl of sterile, nuclease-free water were added to 
each tube with a fourth component: 
4. MultiscribeTM Reverse Transcriptase 1μl/tube  
Samples were then left in a water bath at 37oC for one hour. 
Once the cDNA was synthesised it was stored in -20oC until required for PCR 
and then diluted either 1 in 5 or 1 in 10, with nuclease-free water, depending 
on how much cDNA was needed. 
2.4 Real-Time Polymerase Chain Reaction 
A Polymerase Chain Reaction (PCR) amplifies a specific region of DNA to 
generate thousands or millions of copies of that sequence. In this study, 
quantitative real-time PCR was used to detect both the presence and the 
concentration of RSV within the sample, and to confirm that the gene 
expression had been inhibited through siRNA transfection.  
Kerry Mullis, who went on to gain a Nobel Prize for this in 1993, discovered 
traditional PCR in 1983. Real-Time PCR, applied in this study, was 
introduced by Applied Biosystems in 1996, and has since become the most 
sensitive and precise technique for detecting and quantifying both RNA and 
DNA. Real-Time PCR is able to quantify the DNA during the early stages of 
the reaction, whereas the Traditional PCR requires the use of Agarose gels 
for detection at the end of the final phase. Therefore, difficulty with the gels, 
transfer to membrane, use of radioactive probes and errors formed from 
using the film as a detector have all been eradicated. As with all methods, 
Real-Time PCR has its own limitations, but these can be reduced by 
ensuring uniformity of the components from well-to-well by thoroughly mixing 
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all reagents and dispensing them equally. Dorak’s hint for this is “to use 
calibrated, adjustable pipettors and to have a steady hand!” (165)  
2.4.1  Principles of Polymerase Chain Reaction 
There are four phases in total throughout the PCR amplification: 
1. Baseline – amplification levels below those that can be detected by 
the Real-Time PCR. Although no signal is released during these 
cycles, exponential amplification is taking place. 
2. Exponential – first signals above detection level. If assay is 100% 
efficient, the product should double exactly per cycle to produce a 
number of amplicons. It is during this phase the Real-Time PCR 
quantifies the amplicons. 
3. Linear – efficiency of amplification reduces as the reaction substances 
are consumed. Instead of producing two amplicons, each molecule will 
degrade to 1.95 and continue to decline.  
4. Plateau – reaction ceases and no more products synthesised for 
remaining cycles. 
The threshold level is the point at which the fluorescent signal is detected, 
above the background. This line is set during the exponential phase. Once 
the sample reaches this level, the cycle number is quantified and this is the 
result obtained from the Real-Time PCR – Cycle Threshold (Ct) (165).  
There are three components to the Real-Time PCR instrument: 
1. Light source – establishes receptor dye range detected by instrument 
2. Detection system – spectral range and sensitivity of assay determined 
3. Thermocycling mechanism – monitors speed that assay is run and 
temperature changes between each wells (165). 
2.4.2  Reagents and Processing the Polymerase Chain Reaction 
TaqMan® probes are linear oligonucleotides that anneal to the 
complementary, specific sequence on the template located between the 
Forward and Reverse primers. The advantage of these probes is that they 
are specific for each related assay. These probes are added to the TaqMan® 
gene expression master mix, which contains the enzyme DNA polymerase. 
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Once the primers have attached onto a cDNA template the TaqDNA 
polymerase is rapid to follow and copies the strand. The probe will attach 
itself within the path of the enzyme, and once presented the enzyme cleaves 
the probe.  
TaqMan® probes have two ends, the high energy dye, Receptor, at the 5’ 
end and low energy substance, the Quencher, on the 3’ end. When intact, 
both dyes are in close proximity and the quencher suppresses the signal 
from the receptor dye. Once cleaved by the DNA polymerase, the reporter 
and quencher dyes separate and become further apart. Fluorescent signals 
are released from the receptor as the quencher can no longer inhibit them. 
The TaqMan® probe therefore relies on the enzyme to cleave the two ends 
apart to produce the signal (165)  
The receptor dye that I used was 6-FAM (6-carboxy fluorescein), which is 
successfully excited at 488nM, giving off a strong signal. This type also 
conjugates easily to the oligonucleotide probes (165).  
During my Real-Time PCR experiments, I used a LightCycler 480 instrument 
that holds a 96-well PCR plate. A total of 25μl of reagents were pipetted into 
each well. 
For all the TaqMan® probe assays (Life Technologies; Table 2.1)) used, 
except RSV, 1.25μl was added, with 12.5μl of TaqMan® gene expression 
master mix (Applied Biosystems), per well. The RSV probe volumes were 
different because the three primers, RSVAF (forward), RSVAR (reverse) and 
RSVN-TAQ, were obtained individually and prepared, in contrast to the Life 
Technology probe assays that were supplied ready mixed. The RSV primers 
were designed from Dewhurst-Maridor et al paper (Figure 2.2) (166), and 
synthesised by Sigma. RSVAF and RSVAR primers were mixed together 
with Nuclease-free water in a 1 in 10 dilution. The third primer, a probe with 
FAM dye linked to the 3’ prime end RSVN-TAQ was diluted separately, with 
Nuclease-free water, again in a 1 in 10 dilution. Therefore into each well, 
1.25μl of the mixed RSVAF and RSVAR probes, 1μl of RSVN-TAQ probe 
(Section 3.3.1.1) and 12.5μl of TaqMan® gene expression master mix, was 
added.  
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Figure 2-2: Primers used for PCR-based RSV (N Gene) detection 
 
These three primer sequences are used for RSV detection by real time PCR. This 
figure shows the primer and probe names, sequences and nucleotide position for 
each. The information has been extracted from Dewhurst-Maridor et al published 
work (166). 
 
 
Table 2-1: Product details for other probe assays 
TaqMan® Gene Expression Assay Product Number  
 (Life technologies) 
L32 Hs00388301_m1 
GPR34 Hs00910064_m1 
CNOT4 Hs00203341_m1 
CCR7 Hs01013469_m1 
TRIM15 Hs00264400_m1 
MARCH6 Hs00195391_m1 
UBE2G2 Hs00163326_m1 
RFFL Hs00365160_m1 
RNF168 Hs00288170_m1 
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Table 2-2 A table showing temperature cycle used for amplification. Recommended by 
Applied Biosystems. 
 
 
 
 
 
 
 
 
 
The diluted cDNA was then added to each well to make the total volume up 
to 25μl. Therefore, for all the wells with probes within, except RSV, 11.25μl of 
cDNA was required, whereas 10.25μl of cDNA was used for the RSV probe 
wells. Duplicates were prepared for each sample, so an average could be 
calculated, limiting any possible errors. The L32 probe assay was used as a 
control throughout my work, as RSV does not affect its expression in A549 
cells. 
The PCR plate was then covered with a film and spun in the centrifuge for 
fifteen seconds to ensure all the contents were at the bottom of the well. The 
plate was then placed into the LightCycler 480 Real-Time PCR instrument 
and MxPro software used to complete the procedure. All the wells were 
labelled accordingly with the correct probe and cDNA. The next step was to 
set the correct temperature cycle for the PCR to work efficiently, and this 
depended on the TaqMan® gene expression master mix used. I purchased 
mine from Applied Biosystems and it contained “AmpliTaq Gold® DNA 
Polymerase UP (Ultra Pure), Uracil-DNA Glycosylase (UDG), dTNPs with 
dUTP, Passive Reference 1 and optimized mix components”.  
Table 2-2 shows the temperature cycle and conditions used for amplification.  
 
 
 
 
Step 
 
UDG 
Incubation 
AMPLITaq 
Gold, UP 
Enzyme 
Activation 
 
PCR 
 
HOLD 
 
HOLD 
CYCLE (60 cycles) 
Denature Anneal/ 
Extend 
Time 2 min 10 min 15 sec 1 min 
Temp 50oC 95oC 95oC 60oC 
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2.5 Innate DB 
InnateDB is a search tool available to investigate innate immune responses 
within mammalian species. The database contents of genes, protein, 
interaction and signalling responses have their roles in innate immunity 
highlighted. InnateDB manually curate information by systematically 
reviewing the experimentally-validated interactions from biomedical literature. 
Human interactions especially, are completed with descriptive annotations of 
each molecule, such as published reference and interaction detection. The 
interactions are presented through the visual Cerebral programme, a 
Cytoscape network visualisation software that presents the interaction 
pathways in an intuitive layout. 
The database is freely accessible for public online, and can be used to 
search for specific genes or proteins of interest, with their associated 
interactions and pathways. It includes over 18,000 molecular interactions and 
over 1200 genes annotated relative to innate immunity. This tool has been 
widely available since May 2008, and has been updated regularly since, with 
a large update having taken place in February 2012.  
The database is also a member of the “International Molecular Exchange 
Consortium” (IMEx), which is detected to investigate protein-protein 
interactions, through curative search techniques of published literature and 
combining together onto websites. 
2.6 Statistical Analysis 
Due to the large variation between experiments, statistical analysis was not 
possible. For each gene investigated, the mean (SEM) was calculated and 
graphs produced with GraphPad Prism 6. 
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3  Validation of Candidate Innate Genes in RSV   
Replication using SiRNA Transfection 
3.1 Introduction 
Twenty-six potential innate resistance genes to RSV infection were 
investigated (Section 1.4). Reduced expression of each of these genes, by 
siRNA knockdown had been shown to lead to increased influenza expression 
in infected A549 cells (Prof. R Tripp). This chapter describes the work 
undertaken to determine if any of these genes also influence RSV replication.  
Prof. Tripp kindly provided siRNA with an optimised protocol for its use in 
A549 cells. Prior to siRNA knockdown; I firstly optimised a quantitative real 
time reverse transcription PCR assay to measure RSV replication (in this 
case RSV N gene mRNA expression). Secondly, I determined the optimum 
amount of RSV with which to infect the epithelial cell cultures. Finally, I tested 
the efficiency of siRNA knockdown to ensure effective knockdown was 
occurring. Only then did I measure the effect of knocking down expression of 
each specific gene on RSV replication. 
The online database, InnateDB (www.innateDB.org), was used to look for 
common or shared interaction points and pathways between the 26 genes.  
3.2 Methodology  
3.2.1 SiRNA Transfection Protocol 
SiRNA were used to knockdown candidate innate resistant genes in A549 
cells. This is a temporary knockdown whereby expression of each gene can 
be reduced by up to 80%. The percentage knockdown is calculated by 
comparing expression in siRNA treated and control siRNA treated cells using 
a gene specific TaqMan® PCR assay. The knockdown protocol was kindly 
supplied by Prof. R Tripp, University of Georgia, and lasted five days in total. 
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Day One: 
On day one, A549 cells were transfected with siRNA (Prof. R. Tripp; Life 
Technologies) by firstly preparing a dilute Dharmafect 1 solution (0.4μl/well 
Dharmafect (R Tripp or ThermoSCIENTIFIC) and 14.6μl/well of Hank’s 
Balanced Salt Solution (Sigma), left at room temperature for 5-10mins). 15μl 
of this solution was then pipetted into each well of a 96-well flat-bottomed 
plate. 2.5μl of 2 uM siRNA was added to each well in duplicates so an 
average could be calculated, followed by 2.5μl siRNA dilution buffer (Prof. R. 
Tripp), at a 1 in 5 dilution. This resulted in a total volume of 20μl per well. 
Four wells of A549 cells per plate with no siRNA (two infected and two not 
infected) were included to act as extra controls. For these, to keep the 
volume the same, 5μl of siRNA buffer was used per well. The plate was then 
incubated at room temperature for twenty minutes whilst the A549 cells were 
prepared. 
The cells were seeded as explained in Section 2.1.1 using the cell density of 
15,000 A549 cells per 80μl per well. The plate was then placed into an 
incubator at 37oC, 5% CO2 for two days. 
Day Three: 
On Day three, the cells were infected with RSV following the protocol 
described in Section 2.2.3. For this experiment it was important that the RSV 
concentration was kept the same to minimise any errors. Therefore for each 
RSV batch used, the titre was determined by plaque assay (Section 2.2.2) 
and dilutions tested for infection efficiency by PCR before use. 50μl of dilute 
RSV, containing 15,000 plaque-forming units to give an MOI of 1, in FCS-free 
media was placed into each well. After two hour incubation 100μl of 
supplemented media per well was added to make a total volume of 150μl. 
Following this, the plate was incubated for a further two days at 37oC and 5% 
CO2. 
Day Five: 
Cell supernatants were removed from the wells and placed in individual 1.5ml 
microcentrifuge tubes, before being frozen at -20oc for future work.  
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RNA was extracted from the cells and isolated following the protocols 
described in Section 2.3, using reagent volumes in Table 3.1: 
Table 3-1: Volumes of reagents for RNA isolation 
Reagent Volume (μl)/ sample 
TRIzol® 125 (per well) N.B. The TRIzol® from the 
two duplicated wells was merged into the 
same microcentrifuge tube, to make a 
total of 250μl per tube. 
Chloroform 50 
Isopropanol 200 
Ethanol 500 
 
Messenger RNA was then reverse transcribed to cDNA, as explained in 
Section 2.3.5, and analysed by PCR over 60 cycles (Section 2.4). 
L32 and RSV probes were always used for each cDNA sample analysed.  
Also, if possible, the probes specific to the gene knocked down in that 
sample were used to calculate the percentage knockdown. A control siRNA 
(an irrelevant siRNA not affecting the cell during transfection) was used each 
time for comparison. Expression of L32, RSV and specific probes were all 
compared with the levels expressed in control siRNA transfected cells.  
3.2.2  RSV Dilution 
For each batch of RSV used, an RSV titration experiment was done so that 
the correct RSV dilution could be calculated.  
Day One: 
Using a flat-bottomed 96-well plate, A549 cells were seeded at 20,000 
cells/100μl/well in supplemented medium. In total 18 wells were used, nine 
across and two down. This was because eight dilutions were used with 
repeats and the ninth was the non-infected control. Once seeded, the plate 
was left for 48hours at 37oC and 5% CO2.  
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Day Three: 
The cells were infected. After washing with PBS, nine tubes were set up on 
ice. All nine tubes had 125μl of FCS-free media placed into them. The RSV 
was snap thawed using a 37oC water bath and 25μl of RSV was pipetted into 
the first tube and mixed. 125μl was then taken from the tube and transferred 
to the second tube, where it was mixed and 125μl was removed from the 
second and placed into the third tube. This carried on to the last where the 
mixture was left to give a total of 250μl. The first tube was discarded, and the 
second one therefore was dilution one, and so on.  
Thus, 50μl from tube two/dilution one was placed into the first well on the 
plate, and then its duplicate below. Again, 50μl of the third tube/dilution two 
was added to the next well across, and the one underneath. This carried on 
until eight dilutions were complete. The ninth wells across only required 50μl 
of FCS-free media as they were non-infected.  
The final dilutions were: 
Dilution 1 – 1/10 
Dilution 2 – 1/20 
Dilution 3 – 1/40 
Dilution 4 – 1/80 
Dilution 5 – 1/160 
Dilution 6 – 1/320 
Dilution 7 – 1/640 
Dilution 8 – 1/1280 
After incubation at 37oC for two hours, 100μl of supplemented medium was 
added to each well, and the plate incubated for a further 48hours. 
Day Five: 
RNA was extracted and isolated as in the previous section, using the reagent 
volumes in Table 3.1. After reverse transcription, expression of L32 and RSV 
N gene were measured by real time PCR and data expressed as relative 
RSV expression in comparison to L32. 
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3.2.3  Analysing the Data 
3.2.3.1 Analysing Knockdown Data 
For eight out of the 26 genes, specific probes were used, so that the level of 
siRNA knockdown could be calculated. The probes were chosen based on 
the published literature. 
The percentage of gene left within the A549 cells was calculated in five steps 
as follows: 
1) The average ct value for the house keeping gene L32 minus the 
average ct value for the specific probe for the gene knocked down in 
the sample. E.g. The L32 expression for the GPR34 transfected cDNA 
minus the GPR34 expression (GPR34 probe) of the same cDNA 
sample. 
This step normalised the PCR data within each of the samples by 
accounting for differences in mRNA and therefore cDNA. This 
produced a ct value relative to L32 expression. 
2) The average ct value for L32 expression of the control siRNA 
transfected cDNA minus the average ct value for the specific probe 
expression (e.g. GPR34) against the sample cDNA sample. 
Each probe in the experiment is reacted with the control transfected 
cDNA. This step allows normalisation of the control so it can be 
compared to the value produced in step 1. 
3) The cycle value produced in step 2 minus the cycle value produced in 
step 1. Therefore it is the control value minus the specific value. 
The difference between the control and the test samples expression of 
each gene can be identified here, in cycles. 
4) 2 to the power of n, where n = value determined in step 3. 
This calculation converts the value from a ct number to the fold 
differences. This particular calculation is because every cycle is a 2 
fold change. 
5) 100 divided by n, where n= the value calculated in step 4. 
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This converts the value into percentage, so the percentage of that 
gene left in the A549 cells is known, and confirming the siRNA 
affectivity.  
3.2.3.2 Analysing RSV Expression Data 
For each sample, the percentage RSV N gene expression based on RSV ct 
value was calculated in four steps: 
1) The average ct value for L32 expression of the sample minus the 
average ct value for RSV expression of the same sample. 
This step was done to normalise the PCR data. This calculation 
allowed correction for some of the samples potentially having more 
mRNA and therefore cDNA within them.  
2) The expression value calculated in step 1 for each sample minus the 
control expression in step 1. 
In this step RSV expression was compared to that in the control. 
3) 2 to the power of n, where n = value determined in step 2. 
This is the conversion from ct values to fold differences. This particular 
calculation is because every cycle is a 2 fold change. 
4) N multiplied by 100, where n = value calculate in step 3. 
This is the conversion to RSV N gene expression in percentage. 
As step 2 compares the expression to the control, then the control value will 
become zero at this point. Once it is converted to a numerical value it 
becomes one, and thus is always 100% for each experiment.  
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3.3 Results 
3.3.1  Initial PCR Assays 
3.3.1.1 Determination of optimal RSVN-TAQ probe primer concentration 
It was important for the PCR assays to be optimised. Firstly, different 
concentrations of the RSVN-TAQ probe were analysed so that the 
concentration decided upon would be most favourable. 
Table 3.2 outlines the components and their volumes required at each 
concentration per well, as they are different to the quantities described in 
Section 2.4.2. Each concentration was duplicated to minimise error. 
Figure 3.1 shows RSV expression using different RSVN-TAQ probe primer 
concentrations. Based on these results, it was decided upon that 1μl 
(50pmol) of RSVN-TAQ primer would be used in each PCR well, when 
detecting RSV. 1μl was optimal as it had a good dynamic range allowing 
clear discrimination between positive and negative samples on the PCR 
graph, whilst keeping the amount used comparatively low, to avoid 
unnecessary waste. 
3.3.1.2 Determining if the PCR assay is quantitative 
It was also important to be sure that the PCR assay was quantitative. This 
was done by using the RSV primers to detect RSV expression in samples 
containing different concentrations of RSV. RSV was serially diluted by an 
increasing dilution at 1:10 in nuclease-free water over five samples, and then 
analysed in the PCR machine. 
This experiment confirmed that the PCR assays were within the range of the 
instrument and number of cycles. The observations in Figure 3.2 showed that 
the PCR signal was proportionate to RSV, proving that it was quantitative. 
3.3.1.3 Determination of optimal RSV concentration for use 
The RSV concentration also had to be optimised to ensure the correct 
amount of RSV was used for each experiment. Figure 3.3 shows the RSV N 
gene expression for a number of different RSV concentrations. 
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Table 3-2: Components and quantities (per well) for PCR preparation to optimise 
RSVN-TAQ probe primer 
Concentration RSV AF & 
AR (µl) 
cDNA  
 (µl) 
Gene 
Expression 
Mastermix 
(µl) 
RSVN-TAQ 
Probe 
Primer (µl) 
Nuclease-
Free Water  
 (µl) 
1 1.25 5 12.5 0.5 5.5 
2 1.25 5 12.5 1 5 
3 1.25 5 12.5 2 4 
4 1.25 5 12.5 4 2 
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Figure 3-1: PCR analysis of different RSVN-TAQ primer concentrations 
 
 
 
This shows the Ct values obtained at different RSVN-TAQ primer concentrations 
along each cycle. A total of 40 cycles was used. Duplicates were undertaken at 
each concentration to minimise error. As labelled on the graph, four concentrations 
of RSVN-TAQ primer were tested: 0.5, 1, 2 and 4μl. 
 
 
 
 
 
 
 
 
Ct Value 
4µl 
2µl 
1µl = 
50pmol 
0.5µl 
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Figure 3-2: Five RSV concentrations detected by RSV primers analysed on PCR 
 
 
 
 
This shows the PCR analysis of RSV concentrations diluted by 1:10 over the five 
samples. The ct values are given over 40 PCR cycles.  
 
 
 
 
 
Ct Value 
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Figure 3-3: RSV expression at different RSV titrations in infected A549 cells 
 
 
 
 
 
 
 
 
 
 
 
This shows the RSV expression subtracted away from the L32 expression at each of 
the eight different RSV titrations. The RSV dilutions are as follows: 1) 1/10 2) 1/20 3) 
1/40 4) 1/80 5) 1/160 6) 1/320 7) 1/640 8) 1/1280. 
A polynomial trendline was then inserted, as the graph is not linear, and is slightly 
curved. 
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3.3.2  Knockdown Data 
Relative expression of five genes was initially analysed to confirm that the 
siRNA transfection protocol was successfully knocking down gene 
expression. The predicted knockdown was 60-80%, thus leaving 20-40% 
gene expression remaining within A549 cells. 
3.3.2.1 MARCH6 
Tables 3.3 and 3.4 show results from three experiments done to measure 
MARCH6 expression knockdown. In each experiment all samples were 
measured in duplicate and an average ct value calculated. 
The ct values obtained for L32 and MARCH6 expression in three 
independent experiments are shown in Table 3.3. The calculations convert 
the average ct value into the percentage expression of MARCH6 remaining 
in mRNA extracted from MARCH6 knockdown A549 cells, relative to the 
control. These are shown in Table 3.4, along with the relative values. The 
percentage MARCH6 expression still present is displayed in Figure 3.4, in 
comparison to the control. The remaining percentage expression of MARCH6 
is 21.65%, 28.10% and 12.40%, signifying that MARCH6 was successfully 
knocked down to within or better than the predicted 20-40%.  
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Table 3-3: Ct values for both L32 and MARCH6 probe in both MARCH6 and Control 
knockdown A549 cells 
SiRNA Probe Experiment 1  Experiment 2 
Ct Value 
1 
Ct Value 
2 
Av. Ct Value 
1 
Ct Value 
2 
Av. 
MARCH 
6 
L32 25.02 25.08 25.05 25.66 25.41 25.53 
MARCH 
6 probe 
27.35 27.59 27.47 27.70 27.10 27.40 
Control L32 26.33 26.59 26.46 35.35 34.71 35.03 
MARCH 
6 probe 
26.81 26.52 26.67 34.73 35.40 35.07 
 
SiRNA Probe Experiment 3  
Ct Value 
1 
Ct Value 
2 
Av. 
MARCH 
6 
L32 27.11 27.40 27.26 
MARCH 
6 probe 
27.91 27.98 27.94 
Control L32 35.75 35.14 35.45 
MARCH 
6 probe 
32.84 33.41 33.12 
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Table 3-4: Calculations required showing the percentage of MARCH6 present in the 
MARCH6 knockdown A549 cells 
 
Step Exp 1 
Calc. 
Exp 1  
Result 
Exp 2 
Calc. 
Exp 2 
Result 
Exp 3 
Calc. 
Exp 3 
Result 
MARCH6 
L32 value – 
MARCH6 
probe value 
(Ct) 
25.05 - 
27.47 
-2.42 25.53 - 
27.40 
-1.87 27.26 - 
27.94 
-0.69 
Control 
MARCH6 – 
Control 
MARCH6 
probe (Ct) 
26.46 - 
26.67 
-0.21 35.03 - 
35.07 
-0.04 35.45 - 
33.12 
2.32 
Control – 
Specific (Ct) 
-0.21 -   
-2.42 
2.21 -0.04 -      
-1.87 
1.83 2.32 -     
-0.69 
3.01 
2 to the 
power of n 
2^2.21 4.62 2^1.83 3.56 2^3.01 8.06 
100/n (%) 100/4.62 21.65 100/3.56 28.10 100/8.06 12.40 
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Figure 3-4: The percentage of MARCH6 remaining within MARCH6 knockdown A549 
cells, compared to the control 
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This shows the remaining percentage expression of MARCH6 in three different 
experiments, compared to the control (=100%). MARCH6 has been abbreviated to 
M.6 on the graph. 
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3.3.2.2 GPR34 
The results obtained for GPR34 knockdown are shown in the Table 3.5 
below. The ct values, from two independent experiments, representing the 
L32 and GPR34 expression within both GPR34 and Control knockdown A549 
cells, including the duplicates, are shown and average calculated. 
Table 3.6 shows the calculations from ct values to relative expression of 
GPR34 remaining in GPR34 knockdown cells, and are illustrated in Figure 
3.5. 
These results show that only 15.83% and 0.26% GPR34 expression was 
remaining in the knockdown cells.  
 
Table 3-5: Ct values for both L32 and GPR34 probe in both GPR34 and Control 
knockdown A549 cells. 
 
SiRNA Probe Experiment 1  Experiment 2 
Ct 
Value 1 
Ct 
Value 2 
Av. Ct 
Value 1 
Ct 
Value 2 
Av. 
GPR34 L32 25.29 24.63 24.96 28.37 29.00 28.69 
GPR34 
probe 
39.85 43.51 41.68 44.18 42.61 
 
43.40 
Control L32 24.08 23.95 24.02 30.00 30.50 30.25 
GPR34 
probe 
38.58 37.57 38.08 36.35 
 
- 36.35 
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Table 3-6: Calculations required showing the percentage of GPR34 present in GPR34 
knockdown A549 cells. 
 
Step Experiment 1 
Calculation 
Experiment 1  
Result 
Experiment 2 
Calculation 
Experiment 2 
Result 
GPR34 L32 
value – 
GPR34 probe 
value (Ct) 
24.96 - 41.68 -16.72 28.69 - 43.40 -14.71 
Control L32 – 
Control 
GPR34 probe 
(Ct) 
24.02 - 38.08 -14.06 30.25 - 36.35 -6.10 
Control – 
Specific (Ct) 
-14.06  -            
-16.72  
2.66 -6.10 - -14.71 8.61 
2 to the 
power of n 
2^2.66 6.32 2^8.61 390.72 
100/n (%) 100/6.32 15.83 100/390.72 0.26 
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Figure 3-5: The percentage of GPR34 remaining within GPR34 knockdown A549 cells, 
relative to the control 
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This shows the results, from two independent experiments, illustrating the 
percentage knockdown of GPR34 expression, compared to the control transfected 
cells. 
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3.3.2.3 CCR7 
In Table 3.7 below, the ct values of both L32 and CCR7 expression from 
CCR7 and Control knockdown A549 cells, obtained from PCR analysis, are 
shown. The average ct values from this experiment were calculated and then 
used in Table 3.8 to produce the relative expression of CCR7 remaining in 
the knockdown cells, compared to the control.   
Figure 3.6 shows that the percentage remaining expression of CCR7 relative 
to the control in a single experiment was 28.29%, again within the predicted 
range of 20-40% 
 
 
Table 3-7: Ct values for both L32 and CCR7 probe in both CCR7 and Control 
knockdown A549 cells 
 
 
 
 
 
 
 
SiRNA Probe Experiment 1  
Ct Value 1 Ct Value 2 Average 
CCR7 L32 26.76 26.79 26.77 
CCR7 probe 35.43 36.17 35.80 
Control L32 26.33 26.59 26.46 
CCR7 probe 33.68 33.64 33.66 
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Table 3-8: Calculations required showing the percentage of CCR7 present in the CCR7 
knockdown A549 cells 
 
 
 
 
 
 
 
 
 
 
Step Experiment 1 
Calculation 
Experiment 1  
Result 
CCR7 L32 value – CCR7 probe 
value (Ct) 
26.77 - 35.80 -9.03 
Control L32 – Control CCR7 probe 
(Ct) 
26.46 - 33.66 -7.21 
Control – Specific (Ct) -7.21 - -9.03 1.82 
2 to the power of n 2^1.82 3.53 
100/n (%) 100/3.53 28.29 
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Figure 3-6: The percentage of CCR7 remaining within CCR7 knockdown A549 cells, 
compared to the control 
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This shows CCR7 expression of 28.29% post transfection from A549 cells, 
compared to the control. 
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3.3.2.4 CNOT4 
The results in the following tables show L32 and CNOT4 expression in A549 
cells transfected with either CNOT4 or control siRNA.  
Based on the analysis from two experiments, the relative percentage 
expression of CNOT4 was 6.66% and 3.02%, well below the predicted range 
of 20-40%. 
 
 
Table 3-9: Ct values for both L32 and CNOT4 probe in both CNOT4 and Control 
knockdown A549 cells 
 
SiRNA Probe Experiment 1  Experiment 2 
Ct 
Value 
1 
Ct 
Value 
2 
Average Ct 
Value 
1 
Ct 
Value 
2 
Average 
CNOT4 L32 24.67 24.88 24.78 24.99 24.92 24.95 
CNOT4 
probe 
28.22 28.23 28.23 26.73 27.31 27.02 
Control L32 26.33 26.59 26.46 35.35 34.71 35.03 
CNOT4 
probe 
26.36 25.65 26.00 32.08 32.02 32.05 
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Table 3-10: Calculations required showing the percentage of CNOT4 present in the 
CNOT4 transfected A549 cells 
 
Step Experiment 1 
Calculation 
Experiment 1 
Result 
Experiment 2 
Calculation 
Experiment 2 
Result 
CNOT4 L32 
value – 
CNOT4 
probe value 
(Ct) 
24.78 - 28.23 -3.45 24.95 - 27.02 -2.07 
Control L32 – 
Control 
CNOT4 
probe (Ct) 
26.46 - 26.00 0.46 35.03 - 32.05 2.98 
Control – 
Specific (Ct) 
0.46 - -3.45 3.91 2.98 - -2.07 5.05 
2 to the 
power of n 
2^3.91 15.01 2^5.05 33.06 
100/n (%) 100/15.01 6.66 100/33.06 3.02 
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Figure 3-7: The percentage of CNOT4 remaining within CNOT4 transfected A549 cells, 
relative to the control 
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This shows the percentage expression of CNOT 4 remaining in transfected A549 
cells from two experiments, compared to the control.  
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3.3.2.5 TRIM15 
The ct values of TRIM15 and L32 expression of TRIM15 or control 
knockdown A549 cells, in two independent experiments, are shown in the 
following tables. 
The first experiment showed a total knockdown of 89.59%, leaving a TRIM15 
expression of 10.41%. No TRIM15 expression in the transfected cells was 
observed in Experiment 2, implying that TRIM15 had been successfully 
knocked down below detection levels. 
 
 
Table 3-11: Ct values for both L32 and TRIM15 probe in both TRIM15 and Control 
knockdown A549 cells 
 
SiRNA Probe Experiment 1  Experiment 2 
Ct 
Value 
1 
Ct 
Value 
2 
Average Ct 
Value 
1 
Ct 
Value 
2 
Average 
TRIM15 L32 25.05 25.16 25.11 34.98 35.39 35.19 
TRIM15 
probe 
31.10 30.65 30.88 - - - 
Control L32 35.35 34.71 35.03 26.33 26.59 26.46 
TRIM15 
probe 
37.11 37.96 37.54 32.40 32.01 32.21 
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Table 3-12: Calculations required showing the percentage of TRIM15 present in the 
TRIM15 knockdown A549 cells 
  
Step Experiment 1 
Calculation 
Experiment 1  
Result 
TRIM15 L32 value – TRIM15 
probe value (Ct) 
25.11 - 30.88 -5.77 
Control L32 – Control 
TRIM15 probe (Ct) 
35.03 - 37.54 -2.51 
Control – Specific (Ct) -2.51 - -5.77 3.26 
2 to the power of n 2^3.26 9.61 
100/n (%) 100/9.61 10.41 
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Figure 3-8: The percentage of TRIM15 remaining within TRIM15 knockdown A549 
cells, compared to the control 
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This shows the result from experiment 1, showing the percentage knockdown of 
expression of TRIM15, compared to control. 
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The average percentage expression for each siRNA transfected gene is 
illustrated in Figure 3.9. It can be seen that expression of all five genes was 
knocked down to below 30% of control values. The highest remaining 
expression is CCR7 at 28.29% and the lowest remaining expression is 
CNOT4 at 4.84%. 
 
 
Figure 3-9: The average values for each specific gene expression in transfected A549 
cells 
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The average percentage expression of each of the five genes investigated post-
knockdown.  
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3.3.3  RSV N Gene Expression Data 
RSV N gene expression in knockdown cells was compared to L32 
expression, Ct values in gene specific knockdowns were compared to values 
in matched infected siRNA control samples, with results expressed as a 
percentage of RSV expression in the control. This was used to determine 
whether differential RSV expression had occurred in the knockdown cells. 
In total 26 different genes were analysed and a minimum of three 
experiments performed for each. Full values achieved and calculations for 
each of the genes focused on in Section 3.3.1 are shown below. For each of 
the other 21 genes, the percentage RSV expression obtained in each 
experiment and average has been shown and presented on graphs (Section 
3.3.4), separated into the gene families for comparison, along with the 
respective control. 
3.3.3.1 GCPR Family Data 
GPR34 
Tables 3.13 and 3.14 show the results obtained following GPR34 
knockdown. Ct values from the duplicated wells for L32 and RSV expression 
in each experiment are shown in Table 3.13. The data used to calculate an 
overall percentage of RSV expression relative to the control are shown in 
Table 3.14.  
The mean (SEM) increase in RSV N gene expression in GPR34 knockdown 
cells in the three independent experiments was 244 (+/-89)%. 
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Table 3-13: The PCR Ct values and averages for GPR34 transfected A549 cells over 
three experiments, compared to the Control 
  Experiment 1 Experiment 2 
SiRNA Probe Ct  
Value 1 
Ct  
Value 2 
Av. Ct  
Value 1 
Ct  
Value 2 
Av. 
GPR34 L32 26.23 26.16 26.19 40.99 42.53 41.76 
RSV 27.52 27.35 27.44 42.32 41.42 41.87 
Control L32 26.33 26.59 26.46 38.26 39.31 38.79 
RSV 27.11 27.13 27.12 40.55 - 40.55 
 
  Experiment 3 
SiRNA Probe Ct  
Value 1 
Ct  
Value 2 
Av. 
GPR34 L32 25.29 24.63 24.96 
RSV 29.04 28.59 28.82 
Control L32 24.08 23.95 24.02 
RSV 29.63 29.74 29.68 
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Table 3-14: Conversion from PCR Ct values to percentage of RSV expression within 
GPR34 knockdown A549 cells, compared to the Control 
 
 Experiment 1 Experiment 2 Experiment 3 
        SiRNA 
Step 
GPR34 Control GPR34 Control GPR34 Control 
Average 
L32 Value 
(Ct) 
26.19 26.46 41.76 38.79 24.96 24.02 
Average 
RSV Value 
(Ct) 
27.44 27.12 41.87 40.55 28.82 29.68 
L32 – RSV -1.24 -0.66 -0.11 -1.76 -3.86 -5.67 
Expression 
– Control 
-0.58 0 1.65 0 1.81 0 
2 to the 
power of n 
0.67 1 3.14 1 3.50 1 
Multiply by 
100 (%) 
66.87 100 313.72 100 350.41 100 
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Table 3-15: The average RSV expression percentage in relation to the control when 
GPR34 siRNA is used to transfect A549 cells 
 
siRNA Exp 1 
(%) 
Exp 2 
(%) 
Exp 3 
(%) 
Mean 
(%) 
SEM 
(%) 
GPR34 66.87 313.72 350.41 243.67 89.09 
Control 100 100 100 100 0.00 
 
 
Figure 3-10: A graph to show the percentage RSV expression when infected A549 
cells are transfected with GPR34 siRNA, compared to the control. 
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This shows the average RSV expression from three experiments where GPR34 
transfected cells have been analysed by PCR, compared to the control. The results 
shown are the mean of three values with error bars showing SEM. 
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CCR7 
Table 3.16 contains the duplicated ct values for L32 and RSV expression in 
CCR7 and control knockdown cells, over three independent experiments. 
The RSV N gene expression in the knockdown cells are shown in Tables 
3.17 and 3.18. 
The mean (SEM) RSV N gene expression in CCR7 knockdown cells was 97 
(+/- 44)%. 
 
Table 3-16: The PCR ct values and averages for CCR7 transfected A549 cells over 
three experiments, compared to the control 
  Experiment 1 Experiment 2 
SiRNA Probe Ct  
Value 1 
Ct  
Value 2 
Av. Ct V 
Value 1 
Ct  
Value 2 
Av. 
CCR7 L32 26.76 26.79 26.77 31.56 32.05 31.80 
RSV 26.58 26.53 26.55 37.34 37.39 37.37 
Control L32 26.33 26.59 26.46 35.96 35.80 35.88 
RSV 27.11 27.13 27.12 39.75 40.68 40.21 
 
  Experiment 3 
SiRNA Probe Ct  
Value 1 
Ct  
Value 2 
Av. 
CCR7 L32 26.97 27.19 27.08 
RSV 32.59 32.61 32.60 
Control L32 35.35 34.71 35.03 
RSV 39.74 40.05 39.89 
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Table 3-17: Conversion from PCR ct values to percentage of RSV expression within 
CCR7 transfected A549 cells, compared to the control 
 Experiment 1 Experiment 2 Experiment 3 
          SiRNA 
Step 
CCR7 Control CCR7 Control CCR7 Control 
Average L32 
Value (Ct) 
26.77 26.46 31.80 35.88 27.08 35.03 
Average 
RSV Value 
(Ct) 
26.55 27.12 37.37 40.21 32.60 39.89 
L32 – RSV 0.22 -0.66 -5.56 -4.33 -5.52 -4.86 
Expression – 
Control 
0.88 0 -1.23 0 -0.65 0 
2 to the 
power of n 
1.84 1 0.43 1 0.64 1 
Multiply by 
100 (%) 
184.47 100 42.74 100 63.52 100 
 
 
 
 
 
 
 
 
 
 
 
 97 
Table 3-18: The average RSV expression percentage in relation to the control when 
CCR7 siRNA is used to transfect A549 cells 
 
siRNA Exp 1 
(%) 
Exp 2 
(%) 
Exp 3 
(%) 
Mean 
(%) 
SEM 
(%) 
CCR7 184.47 42.74 63.52 96.91 44.19 
Control 100 100 100 100 0.00 
 
Figure 3-11: A graph to show the % RSV expression when infected A549 cells are 
transfected with CCR7 siRNA, compared to the control. 
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This shows the RSV expression of CCR7 transfected A549 cells, compared 
to the control. The bar illustrates the mean percentage value taken from the 
three experiments, with SEM error bars. 
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3.3.3.2 Ubiquitin E3 Ligase 
CNOT4 
Ct values and averages of L32 and RSV expression in CNOT4 and control 
knockdown cells are shown in Table 3.19. These average values are used to 
calculate the percentage RSV N gene expression at mRNA level in A549 
cells transfected with CNOT4 and control siRNA (Tables 3.20 and 3.21) 
The RSV N gene expression mean (SEM) in CNOT4 knockdown cells was 
771 (+/- 736)%. 
 
Table 3-19: The PCR ct values and averages for CNOT4 knockdown A549 cells over 
three experiments, compared to the control 
  Experiment 1 Experiment 2 
SiRNA Probe Ct  
Value 1 
Ct  
Value 2 
Av. Ct  
Value 1 
Ct  
Value 2 
Av. 
CNOT4 L32 24.67 24.88 24.78 24.99 24.92 24.95 
RSV 27.02 27.14 27.08 31.35 31.12 31.23 
Control L32 26.33 26.59 26.46 35.35 34.71 35.03 
RSV 27.11 27.13 27.12 39.74 40.05 39.89 
 
  Experiment 3 
SiRNA Probe Ct  
Value 1 
Ct  
Value 2 
Av. 
CNOT4 L32 39.62 39.28 39.45 
RSV 38.05 37.85 37.95 
Control L32 36.79 37.17 36.98 
RSV 39.97 39.97 39.97 
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Table 3-20: Conversion from PCR ct values to percentage of RSV expression within 
CNOT4 knockdown A549 cells, compared to the control 
 
 Experiment 1 Experiment 2 Experiment 3 
       SiRNA 
Step 
CNOT4 Control CNOT4 Control CNOT4 Control 
Average 
L32 Value 
(Ct) 
24.78 26.46 24.95 35.03 39.45 36.98 
Average 
RSV Value 
(Ct) 
27.08 27.12 31.23 39.89 37.95 39.97 
L32 – RSV -2.3 -0.66 -6.28 -4.86 1.50 -2.99 
Expression 
– Control 
-1.64 0 -1.42 0 4.49 0 
2 to the 
power of n 
0.32 1 0.37 1 22.44 1 
Multiply by 
100 (%) 
32.11 100 37.45 100 2243.99 100 
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Table 3-21: The average RSV expression percentage in relation to the control when 
CNOT4 siRNA is used to transfect A549 cells 
 
siRNA Exp 1 
(%) 
Exp 2 
(%) 
Exp 3 
(%) 
Mean 
(%) 
SEM 
 (%) 
CNOT4 32.11 37.45 2244.00 771.18 736.41 
Control 100 100 100 100 0.00 
 
 
Figure 3-12: A Graph to show the % RSV expression when infected A549 cells are 
transfected with CNOT4 siRNA, compared to the control. 
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This bar chart shows the mean (SEM) RSV expression for CNOT4 siRNA, 
compared to the control.  
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MARCH6  
Table 3.22 shows the duplicated ct values of L32 and RSV expression in 
MARCH6 and control knockdown cells, over three independent experiments. 
The RSV N gene expression of these knockdown cells is shown in Tables 
3.23 and 3.24. 
The mean (SEM) decrease in RSV N gene expression in MARCH6 
knockdown cells was 70 (+/-18)%. 
 
Table 3-22: The PCR ct values and averages for MARCH6 transfected A549 cells over 
three experiments, compared to the control 
  Experiment 1 Experiment 2 
SiRNA Probe Ct  
Value 1 
Ct  
Value 2 
Av. Ct  
Value 1 
Ct  
Value 2 
Av. 
MARCH 
6 
L32 25.02 25.08 25.05 25.66 25.41 25.53 
RSV 27.13 27.16 27.14 30.43 30.35 30.39 
Control L32 26.33 26.59 26.46 35.34 34.71 35.03 
RSV 27.11 27.13 27.12 39.74 40.05 39.89 
 
  Experiment 3 
SiRNA Probe Ct  
Value 1 
Ct  
Value 2 
Av. 
MARCH 
6 
L32 27.11 27.40 27.26 
RSV 28.68 28.70 28.69 
Control L32 35.75 35.14 35.45 
RSV 36.86 35.90 36.38 
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Table 3-23: Conversion from PCR ct values to percentage of RSV expression within 
MARCH6 knockdown A549 cells, compared to the control 
 Experiment 1 Experiment 2 Experiment 3 
        SiRNA 
Step 
MARCH 
6 
Control MARCH 
6 
Control MARCH 
6 
Control 
Average L32 
Value (Ct) 
25.05 26.46 25.53 35.03 27.26 35.45 
Average 
RSV Value 
(Ct) 
27.14 27.12 30.39 39.89 28.69 36.38 
L32 – RSV -2.09 -0.66 -4.86 -4.86 -1.43 -0.94 
Expression – 
Control 
-1.43 0 0.01 0 -0.50 0 
2 to the 
power of n 
0.37 1 1.00 1 0.71 1 
Multiply by 
100 (%) 
37.17 100 100.44 100 70.95 100 
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Table 3-24: The average RSV expression percentage in relation to the control when 
MARCH6 siRNA is used to transfect A549 cells 
 
siRNA Exp 1 
(%) 
Exp 2 
(%) 
Exp 3 
(%) 
Mean 
(%) 
SEM 
 (%) 
MARCH6 37.17 100.44 70.95 69.52 18.28 
Control 100 100 100 100 0.00 
 
 
Figure 3-13: A graph to show the % RSV expression when infected A549 cells are 
transfected with MARCH6 siRNA, compared to the control. 
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This demonstrates the RSV expression values produced in MARCH6 and control 
transfected A549 cells. The expression has been converted from ct values given by 
the PCR machine, to percentage, by a number of calculations, therefore showing 
the mean (SEM) RSV N gene expression, relative to the control 
 
TRIM15 
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Tables 3.25 and 3.26 contain the ct values for L32 and RSV expression in 
TRIM15 and control knockdown cells, and the calculations required to obtain 
the final percentage of RSV N gene expression relative to the control. 
The mean (SEM) of RSV N gene expression, over three independent 
experiments, was 67 (+/-20)%. 
Table 3-25: The PCR ct values and averages for TRIM15 transfected A549 cells over 
three experiments, compared to the control 
 
  Experiment 1 Experiment 2 
SiRNA Probe Ct  
Value 1 
Ct  
Value 2 
Av. Ct  
Value 1 
Ct  
Value 2 
Av 
TRIM 
15 
L32 34.99 35.39 35.19 25.05 25.16 25.11 
RSV 35.54 37.27 36.41 31.63 31.69 31.66 
Control L32 26.32 26.59 26.46 35.35 34.71 35.03 
RSV 27.11 27.13 27.12 39.74 40.05 39.89 
 
  Experiment 3 
SiRNA Probe Ct  
Value 1 
Ct  
Value 2 
Av. 
TRIM 
15 
L32 26.12 26.28 26.20 
RSV 26.98 27.25 27.11 
Control L32 35.75 35.14 35.45 
RSV 36.86 35.90 36.38 
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Table 3-26: Conversion from PCR ct values to percentage of RSV expression within 
TRIM15 knockdown A549 cells, compared to the control 
 
 Experiment 1 Experiment 2 Experiment 3 
      SiRNA 
Step 
TRIM15 Control TRIM15 Control TRIM15 Control 
Average 
L32 Value 
(Ct) 
35.19 26.46 25.11 35.03 26.20 35.45 
Average 
RSV Value 
(Ct) 
36.41 27.12 31.66 39.89 27.11 36.38 
L32 – RSV -1.22 -0.66 -6.55 -4.86 -0.91 -0.94 
Expression 
– Control 
-0.56 0 -1.69 0 0.02 0 
2 to the 
power of n 
0.68 1 0.31 1 1.02 1 
Multiply by 
100 (%) 
67.76 100 30.96 100 101.53 100 
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Table 3-27: The average RSV expression percentage in relation to the control when 
TRIM15 siRNA is used to transfect A549 cells 
 
siRNA Exp 1 
(%) 
Exp 2 
(%) 
Exp 3 
(%) 
Mean 
(%) 
SEM 
TRIM15 67.76 30.96 101.53 66.75 20.38 
Control 100 100 100 100 0.00 
 
Figure 3-14: A graph to show the % RSV expression when infected A549 cells are 
transfected with TRIM15 siRNA, compared to the control. 
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This bar chart shows the mean percentage RSV expression, plus SEM error bars, of 
TRIM15 and control knockdown A549 cells. 
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3.3.4  Overview of Knockdown Data 
For the other 21 genes investigated, the RSV expression for each of the 
three or, in one case, four experiments has been shown below, along with 
the subsequent averages, shown in Tables 3.28 to 3.33. The averages are 
then analysed to determine whether RSV N gene expression is influenced by 
the knockdown in expression of these specific genes. 
The data has been structured into the four families, so that the members can 
be compared to each other, and the control. 
3.3.4.1 Kinase Family 
The kinase family only contains one of the genes investigated, MAP3K1. The 
RSV expression for each of the three experiments is shown in Table 3.28. 
The mean (SEM) increase of RSV N gene expression in MAP3K1 
knockdown cells was 156 (+/- 27)%. 
 
Table 3-28: Average percentage of RSV Expression, after three experiments, when 
MAP3K1 of Kinase Family is transfected in A549 cells. 
 
SiRNA Experiment 1 
(%) 
Experiment 2 
(%) 
Experiment 3 
(%) 
Mean 
 (%) 
SEM 
 (%) 
MAP3K1 188.14 180.80 98.64 155.86 26.69 
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Figure 3-15: Average percentage of RSV expression of MAP3K1 transfected A549 cells 
in relation to the control 
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This shows the percentage RSV expression for MAP3K1 transfected A549 cells, in 
relation to the control. The error bars illustrate the SEM. 
 
 
3.3.4.2 Phosphatase Family 
Similar to the kinase family, there is only one member of the phosphatase 
family included in the 26 genes being studied.  The average RSV expression 
results, obtained from the original ct values of L32 and RSV expression via 
PCR, have been shown in Table 3.29.  
The mean (SEM) RSV N gene expression, over three independent 
experiments, in PPM1H knockdown cells was 347 (+/- 219) %, relative to the 
control. 
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Table 3-29: Average percentage of RSV expression, after three experiments, when 
PPM1H of Phosphatase Family is transfected in A549 cells 
 
SiRNA Experiment 
1 
Experiment 
2 
Experiment 
3 
Mean 
 (%) 
SEM 
 (%) 
PPM1H 781.23 182.83 76.99 347.02 219.25 
 
 
 
Figure 3-16: Average percentage of RSV Expression of PPM1H knockdown A549 cells 
in relation to the control 
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The mean RSV expression and SEM error bars are presented on the above graph. 
The left bar is the control transfected cells, which always equals 100%, and on the 
right is the PPM1H transfected cells. 
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3.3.4.3 GCPR Family 
The influence of six members of the GCPR family on RSV expression was 
analysed. The values shown in Table 3.30 represent the RSV expression 
values obtained from the three experiments for each gene knockdown. These 
values have been calculated from the L32 and RSV expression ct values 
analysed through PCR. The averages shown in Table 3.30 were calculated 
over the three experiments and are illustrated in Figure 3.17. 
This data shows the highest mean (SEM) RSV N gene expression was in 
CXCR3 knockdown cells with a result of 315 (+/- 177)%. This was followed 
by GPR34 and HRH4 knockdown cells, which had a mean (SEM) increase in 
RSV N gene expression of 244 (+/- 89)% and 212 (+/- 171)%, respectively. 
The mean (SEM) RSV N gene expression in HRH2 and CX3CR1 knockdown 
cells was 126 (+/- 63)% and 124 (+/- 46)%, respectively. The only decrease 
in RSV N gene expression, in GCPR family, was in CCR7 knockdown cells 
with a mean (SEM) of 97 (+/- 44)%. 
 
Table 3-30: Average percentage of RSV expression, after three experiments, when 
genes of GCPR Family are knocked down in A549 cells 
 
SiRNA Experiment 
1 
Experiment 
2 
Experiment 
3 
Mean 
 (%) 
SEM 
 (%) 
GPR34 66.87 313.72 350.41 243.67 89.03 
HRH2 252.98 62.63 62.77 126.13 63.43 
HRH4 554.39 30.91 50.59 211.96 171.31 
CXCR3 133.49 142.35 668.93 314.92 177.02 
CX3CR1 177.73 163.44 32.12 124.43 46.34 
CCR7 184.47 42.74 63.52 96.91 44.19 
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Figure 3-17: Average percentage of RSV expression from A549 cells transfected with 
siRNA from the GCPR family, relative to the control  
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This shows the mean RSV expression values taken over three experiments 
when each gene expression has been knocked down. All six genes belong to 
the GPCR family. All points are presented so they can be compared to the 
control with the addition of SEM error bars. 
 
3.3.4.4 Ubiquitin E3 Ligase 
The results for the Ubiquitin E3 Ligases are shown in one table, but three 
different graphs, because of the large variation in RSV N gene expression 
seen with these genes. 
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Table 3-31: Average percentage of RSV expression, after three experiments, when 
genes of Ubiquitin E3 Ligase Family are knocked down in A549 cells 
 
SiRNA Exp 
 1 
Exp 
2 
Exp 
 3 
Exp 
4 
Mean 
 (%) 
SEM 
 (%) 
RNF149 76.58 14.72 53.10  48.13 18.03 
RNF150 150.20 52.79 213.80  138.93 46.82 
MARCH6 37.17 100.44 70.95  69.52 18.28 
HR 38.43 20.70 47.08  35.40 7.76 
LOC 
643904 
134.35 3.63 175.09  104.36 51.72 
PHF21A 95.01 454.76 79.41  209.73 122.60 
RAD18 119.46 163.89 90.27  124.54 21.40 
TOPORS 233.99 14.34 69.37  105.90 65.99 
TRIM15 67.76 30.96 101.53  66.75 20.38 
TRIM43 785.68 235.50 3.91  341.70 231.84 
TRIM73 45.56 43.67 200.78  96.67 52.06 
CNOT4 32.11 37.45 2244.00  771.18 736.41 
PCGF5 1914.57 182.99 180.05 54.87 583.12 444.82 
RUFY1 162.37 4688.97 105.07  1652.14 1518.51 
TRIM37 3284.04 47.91 52.73  1128.23 1077.91 
RNF168 330.09 1245856 88.28  415424.9 415215.70 
RFFL 1766125 195.74 124.07  588814.9 588655.10 
TRIM2 886.79 696303 90.45  232426.8 231938.30 
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Mean RSV expression for the eleven lowest Ubiquitin E3 Ligases was 
between 35.40 and 341.70% and is shown in Figure 3.18. Mean RSV 
expression for these genes varied considerably, with five showing down-
regulation and six, up-regulation. For some genes there was much inter-
experiment variation as well signified by the large standard errors of mean. 
 
Figure 3-18: Average percentage of RSV expression from A549 cells transfected with 
siRNA from the Ubiquitin E3 Ligase Family, relative to the control  
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This displays the mean (SEM) RSV N gene expression values from cells transfected 
with one of the eleven members of the ubiquitin E3 ligase family, relative to the 
control. 
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Results for the next four genes with the next highest RSV expression are 
shown in Figure 3.19. All experiments were repeated three times apart from 
the PCGF5, which was repeated four times. 
All four genes showed up-regulation of RSV N gene expression with a 
variation of 445 and 1519%. 
 
Figure 3-19: Average percentage of RSV expression from A549 cells transfected with 
siRNA from the Ubiquitin E3 Ligase Family, relative to the control 
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Mean (SEM) RSV expression for four ubiquitin E3 ligase members are displayed in 
the above graph relative to the control. 
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Figure 3.20 shows the three genes, which when knocked down, caused the 
greatest increase in RSV expression; RNF168, RFFL or TRIM2. 
The mean (SEM) increase in RSV N gene expression for RNF168, RFFL or 
TRIM2 knockdown cells was 415425 (+/-415216)%, 588815 (+/-588655)% 
and 232426 (+/-231938)%, respectively.  
 
Figure 3-20: Average percentage of RSV expression from A549 cells transfected with 
siRNA from the Ubiquitin E3 Ligase Family, relative to the control 
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Mean (SEM) change in RSV expression following knockdown of RNF168, RFFL and 
TRIM2 ubiquitin ligase expression relative to the control. 
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Figure 3.21 shows the relative RSV N gene expression for all genes from all 
four families following knockdown plotted in a logarithmic scale. 
 
 
Figure 3-21: RSV N gene expression for all genes knocked down by siRNA 
 
 
Mean (SEM) RSV N gene expression displayed on a logarithmic scale for each of 
the 26 gene expression knockdowns.  
 
 
 
 
 
 
Gene Expression Knocked-Down  
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3.4 Discussion 
This chapter describes how knocking down expression of each specific gene 
affects RSV N gene expression. 
Firstly, it was necessary to validate quantitative real-time reverse 
transcription PCR assay to measure RSV expression. Next, determination of 
how much RSV should be used to infect cells and, thirdly, to validate the 
siRNA knockdown protocol before being able to assess the effect of each 
specific gene on RSV expression. 
3.4.1  Optimisation of PCR Assay 
To ensure that the correct amount of RSVN-TAQ probe was used in our 
experiments, I tested four different amounts of probe: 0.5, 1, 2 and 4µl. 1μl 
(50pmol) was chosen for future use, because this provided a high level of 
discrimination between the negative background and positive signal strength. 
A potential limitation to our study was that we only used one RSV gene as a 
surrogate for overall RSV replication; we do not know whether all RSV genes 
are transcribed at the same rate. This could be improved by adding PCRs for 
other RSV genes or by focusing on the plaque assay technique. 
It was also important to show that the PCR assays were quantitative, which I 
did by measuring RSV N gene expression by PCR in five different RSV 
dilutions. Figure 3.2 illustrates that the signal obtained by PCR was 
proportional and reflected the amount that the RSV sample had been diluted. 
3.4.2  Determination of the amount of RSV used to infect A549 cultures 
My objective in these experiments was to determine the amount of RSV 
needed to infect A549s that would allow changes in RSV N gene expression 
to be measured within the PCR range.  Figure 3.3 illustrates the RSV 
expression at different dilutions. A 1:50 RSV dilution was chosen, which gave 
an MOI (Section 2.2.2) of 1. A MOI of one is ideal, because there is one viral 
particle to each cell, ensuring complete infection. If the MOI is above one, it 
may risk infecting the cells too much, causing death and therefore no mRNA 
would be available to extract. 
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3.4.3  Successful knockdown of gene expression by siRNA treatment.  
I next wanted to demonstrate the knockdown of gene expression successfully 
occurred when cells were treated with siRNA. For my analysis to be valid it 
was important to show that siRNA transfection knocked down specific gene 
expression efficiently. The expected maximal knockdown using siRNA was 
greater than or equal to 60%. 
In section 3.3.2, the results for five randomly selected genes, which were 
successfully knocked down, are shown. The most effective knockdown was 
for CNOT4, which was knocked down by 95.16%, leaving only 4.84% 
CNOT4 expression within transfected A549 cells. The least effective 
knockdown was for CCR7, but this still only left 28.29% CCR7 expression 
remaining, comfortably within the predicted knockdown range, and reassured 
us that the siRNA technique and reagents were working effectively. 
The expression assays were performed four days post knockdown and two 
days post RSV infection. A possible reason for our knockdowns generally 
exceeding the predicted range may be that mRNA expression for each gene 
may have reduced further over the 48 hour time period post RSV infection. 
However, as the knockdown levels were higher than expected, the protocol 
was not altered or optimised further. 
A limitation to this work is that RSV N gene expression was used as a 
surrogate for RSV replication. Showing that RSV protein expression was 
differentially affected, using a western blotting technique, would strengthen 
our data. 
3.4.4  Influence that inhibition of gene expression has on RSV 
expression 
Having demonstrated inhibition of gene expression following siRNA 
treatment, the influence that knockdown of gene expression has on RSV 
expression was measured by real-time PCR. 
The only member of the Kinase family to be investigated, MAP3K1, showed 
up-regulation of RSV N gene expression by 50% compared to the control. 
Similarly, knockdown of PPM1H, the only phosphatase family member, 
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increased mean RSV N gene expression by over three times. Following 
knockdown of the GPCR family, RSV expression for all genes (apart from 
CCR7, which showed a slight drop in relative RSV expression to 97%) 
increased compared to the control value. CXCR3 knockdown had the 
greatest effect, increasing RSV N gene expression by over three times that of 
the control.  
The ubiquitin E3 ligases showed the greatest variation of the four families 
studied. 18 members of this family were investigated with five showing down-
regulation of RSV N gene expression, implying that they do not have 
protective role in RSV infection, in contrast to influenza. Figure 3.20 shows 
the three E3 ligases whose knockdown had the greatest effect on RSV N 
gene expression. Although RSV gene expression following RNF168, RFFL or 
TRIM2 knockdown showed large variation, the effect of these knockdowns 
dwarfed those seen for the other genes (Figure 3.21). 
Prof. Tripp has already shown that each of these genes affects influenza 
replication when knocked down. He analysed the change in expression by Z 
score, but this was not possible with our results because to do this would 
have required more than three experiments for each gene and this was not 
possible within the time period of this MPhil year. 
3.4.5  Use of InnateDB to investigate pathways that may inhibit RSV 
 replication 
InnateDB is an online database, which provides information on genes 
involved in innate immunity to infection and associated biochemical pathways 
and protein-protein interactions. We used this database to investigate how 
each gene might act to inhibit RSV replication. Figure 3.22 shows the protein-
protein interactions associated with the Ubiquitin E2 ligase, UBE2G2. This 
protein interacts with three proteins that we found up-regulated RSV gene 
expression when individually knocked down: RNF168 (415,414%), RFFL 
(588,814%) and TRIM43 (342%). 
 
In Chapter 4, I focus on the two genes within the UBE2G2's 'pathway' that 
had the greatest affect on RSV replication when knocked down, namely 
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RNF168 and RFFL. Chapter 6 focuses on GPR34 because knockdown of 
this protein was observed to cause morphological changes in A549 cells. 
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Figure 3-22: The protein-protein interactions of UBE2G2 (supplied by InnateDB) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This figure shows the protein-protein interactions involved with the ubiquitin 
E2 ligase, UBE2G2. Potential protein-protein interactions are shown by 
dotted lines. 
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4  The influence of UBE2G2, RFFL and RNF168 
knockdown on RSV N gene expression 
4.1 Introduction 
The aim of the experiments included in this chapter were to investigate how 
UBE2G2 influenced RSV replication, and to confirm the effects of RNF168 
and RFFL by increasing the number of replicates. 
UBE2G2, an E2 ligase, is found in all human tissues, and is a key component 
of the endoplasmic reticulum-associated degradation (ERAD) pathway (167). 
Misfolded or unassembled proteins within the endosplasmic reticulum (ER) 
are targeted by the ERAD pathway for K48-linked polyubiquitination, which 
marks a protein for proteasomal breakdown. This proteasomal breakdown 
involves the activation of the ubiquitin ligases E1, E2 and E3, resulting in the 
formation of covalent bonds between the ubiquitin and the lysine residues 
within the target protein (Figure 1.5) (167). 
Signal transduction and cell cycle activities such as proliferation and 
apoptosis rely on an efficient ERAD pathway (167, 168). Ubiquitins are not 
present in ER lumen, which means target proteins within the ER must be 
relocated to the cytoplasm before having the K48-polyubiquitin chain 
attached. UBE2G2’s suggested role is in assembling the K48-linked ubiquitin 
chain before interaction with E3 ligases such as RNF168 or RFFL  (167).  
There are over thirty human E2 enzymes identified to date and all contain an 
active site cysteine residue essential for ubiquitin attachment through the 
thiolester bond. The catalytic core, approximately 150 amino acids in size, 
contains the cysteine residue, plus α and β folds (167, 169). The E2 proteins 
are ubiquitin-conjugating enzymes, where the activated ubiquitin is 
transferred from the E1, ubiquitin-activating enzyme, to the active cysteine 
residue. 
E2 enzymes are subdivided into four groups, classified by the presence or 
absence of the C- and N-terminal extensions in their core sequence (169): 
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Class I – small members of the E2 enzyme family, which consists almost 
totally of the core domain. 
Class II – includes a C-terminal extension from the core domain. 
Class III – includes an N-terminal extension from the core domain. 
Class IV – includes both C- and N- terminal extensions from the core domain. 
UBE2G2, also known as UBC7, encodes for the ubiquitin-conjugating 
enzyme E2 G2, which has a molecular weight of 18.6kDa and compromises 
165 amino acids. This gene, located on chromosome 21, band q22.3, 
interacts with a number of RING-finger E3 ligases (169).  
The crystal structure of UBE2G2 contains a 13-residue sequence insertion 
below the active site cysteine, which also includes four conserved acidic 
residues, essential to its catalytic function. Substitution of these residues 
inhibits assembly of the poly-ubiquitin chain, but little more is known about 
how this function occurs. Above the active site, all E2 ligases have an 
asparagine residue (N81 in UBE2G2) necessary for catalytic function (112, 
167-169). 
4.2 Materials and Methods 
4.2.1  Knockdown Protocol 
UBE2G2 siRNA was obtained from Life Technologies. The five-day 
knockdown protocol outlined in Section 3.2.1 was again followed for 
UBE2G2, RNF168 and RFFL. Due to the large variation in RSV expression 
seen following previous knockdowns, six duplicates of A549 cells were 
transfected with UBE2G2, RNF168 and RFFL siRNA.  
4.3 Results 
4.3.1  Knockdown Data 
Table 4.1 shows the average ct values for each of the three genes of interest 
and the control gene L32, from each of the six experiments. The mean (SEM) 
percentage knockdown for each gene is shown in Table 4.2 and Figure 4.1. 
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Table 4-1: Average ct values for L32, RFFL, RNF168 and UBE2G2 expression in 
knockdown A549 cells over six experiments 
 
SiRNA Probe Exp 1  
 (Ct) 
Exp 2 
 (Ct) 
Exp 3 
 (Ct) 
Exp 4 
 (Ct) 
Exp 5 
 (Ct)  
Exp 6 
 (Ct) 
RFFL L32 27.55 27.34 26.73 28.20 27.20 28.15 
RFFL 30.69 31.06 29.94 33.10 30.38 30.76 
RNF168 L32 28.30 26.79 26.57 26.77 26.82 28.90 
RNF168 33.15 32.77 30.49 30.21 29.53 33.56 
UBE2G2 L32 25.95 38.05 26.59 27.18 29.54 28.06 
UBE2G2 29.24 40.48 30.02 30.25 33.20 31.14 
Control L32 27.31 27.71 28.21 28.31 29.31 27.14 
RFFL 27.26 27.59 28.02 28.77 29.57 26.97 
RNF168 28.84 29.41 28.88 30.22 31.41 28.32 
UBE2G2 27.87 28.76 29.40 29.70 30.67 28.63 
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Table 4-2: Calculation steps from ct values to percentage of remaining gene 
expression within A549 cells for RFFL, RNF168 and UBE2G2. 
 
Step  Exp 1 Exp 2 Exp 3 Exp 4 Exp 5 Exp 6 
Specific: 
L32 - 
Probe 
RFFL -3.14 -3.72 -3.21 -4.90 -3.18 -2.61 
RNF168 -4.85 -5.99 -3.93 -3.44 -2.71 -4.66 
UBE2G2 -3.30 -2.43 -3.43 -3.07 -3.66 -3.08 
Control: 
L32 - 
probe 
RFFL 0.05 0.12 0.19 -0.46 -0.26 0.17 
RNF168 -1.54 -1.70 -0.68 -1.91 -2.11 -1.19 
UBE2G2 -0.56 -1.05 -1.19 -1.39 -1.36 -1.50 
Control - 
Specific 
RFFL 3.19 3.84 3.40 4.44 2.92 2.78 
RNF168 3.32 4.29 3.25 1.53 0.60 3.48 
UBE2G2 2.74 1.38 2.24 1.68 2.30 1.59 
2 to the 
power of 
n 
RFFL 9.09 14.32 10.56 21.63 7.57 6.87 
RNF168 9.95 19.49 9.51 2.89 1.52 11.12 
UBE2G2 6.66 2.60 4.71 3.20 4.91 3.00 
100/n 
(%) 
RFFL 11.00 6.98 9.47 4.62 13.21 14.56 
RNF168 10.05 5.13 10.51 34.63 65.98 8.99 
UBE2G2 15.02 38.42 21.24 31.21 20.38 33.33 
 
The mean (SEM) of the knockdown values for each gene relative to the 
control, over six experiments are shown in Figure 4.1. The average RFFL, 
RNF168 and UBE2G2 gene expression remaining was 10 (+/-1.5)%, 23 (+/-
10)% and 27 (+/-4)%, respectively. 
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Figure 4-1: Remaining gene expression within transfected cells, post-transfection of 
RFFL, RNF168 and UBE2G2  
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This shows the remaining gene expression within transfected A549 cells. The siRNA 
used, in order of above graph, was control, RFFL, RNF168 and UBE2G2. The bars 
show the mean of the six experiments, with SEM error bars. 
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4.3.2  RSV Expression 
Having confirmed gene knockdown, I investigated its effect on RSV 
replication and expression in knocked down cultures. The L32 and RSV 
expression ct values are shown in Table 4.3 for each of the gene expression 
knockdown in all six experiments. The averages were calculated so that ct 
values could be converted into percentage RSV expression (Table 4.4). 
Figure 4.2 shows RSV N gene expression following knockdown of the three 
genes. Following knockdown of RNF168 and UBE2G2, RSV expression 
increased by 180 (+/-51)% and 113 (+/-25)%, respectively. RFFL transfection 
resulted in a slight down-regulation of RSV expression (96 (+/-17)%). 
Variation between experiments was much less than seen previously. 
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Table 4-3: The ct values and averages for the gene expression of RFFL, RNF168 and 
UBE2G2 in knockdown cells, related to control. 
 (This table continues on to page 129) 
 
SiRNA Probe Experiment 1 Experiment 2 
Ct 
Value 1 
Ct 
Value 2 
Av. Ct 
Value 1  
Ct 
Value 2 
Av. 
RFFL L32 27.23 27.87 27.55 27.37 27.30 27.34 
RSV 30.82 31.20 31.01 29.98 29.97 29.98 
RNF168 L32 28.18 28.42 28.30 26.75 26.82 26.79 
RSV 31.62 31.61 31.62 29.24 29.57 29.41 
UBE2G2 L32 25.91 25.98 25.95 37.74 38.35 38.05 
RSV 28.90 28.89 28.90 39.49 39.46 39.48 
Control L32 27.38 27.23 27.31 27.69 27.72 27.71 
RSV 30.29 30.16 30.23 30.31 30.18 30.25 
  Experiment 3 Experiment 4 
Ct 
Value 1 
Ct 
Value 2 
Av. Ct 
Value 1  
Ct 
Value 2 
Av. 
RFFL L32 26.73 26.72 26.73 28.23 28.17 28.20 
RSV 30.21 29.69 29.95 31.75 31.00 31.38 
RNF168 L32 26.61 26.52 26.57 26.74 26.80 26.77 
RSV 28.79 28.52 28.66 29.64 28.87 29.26 
UBE2G2 L32 25.86 27.32 26.59 26.99 27.36 27.18 
RSV 30.68 30.83 30.76 30.30 30.69 30.50 
Control L32 28.28 28.13 28.21 28.15 28.47 28.31 
RSV 32.56 31.38 31.97 31.56 31.85 31.71 
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Table 4-3 continued: The ct values and averages for the gene expression of RFFL, 
RNF168 and UBE2G2 in knockdown cells, related to control. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SiRNA Probe Experiment 5 Experiment 6 
Ct Value 
1  
Ct Value 
2 
Av. Ct 
Value 1 
Ct Value 
2 
Av. 
RFFL L32 27.33 27.07 27.20 28.13 28.17 28.15 
RSV 30.37 31.48 30.93 31.38 31.92 31.65 
RNF168 L32 26.85 26.79 26.82 28.53 29.27 28.90 
RSV 29.26 28.87 29.07 31.18 31.56 31.37 
UBE2G2 L32 29.36 29.72 29.54 28.09 28.02 28.06 
RSV 32.86 33.13 33.00 31.21 31.27 31.24 
Control L32 29.35 29.26 29.31 27.18 27.09 27.14 
RSV 33.77 32.89 33.33 28.83 28.97 28.90 
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Table 4-4: RSV expression for each experiment, after knockdown, and the subsequent 
average value. 
 
SiRNA Exp 1 
(%) 
Exp 2 
(%) 
Exp 3 
(%) 
Exp 4 
(%) 
Exp 5 
(%) 
Exp 6 
(%) 
Av. (%) 
RFFL 68.78 93.30 145.40 116.47 123.11 30.04 96.20 
RNF168 76.05 94.61 319.32 187.90 343.43 61.34 180.44 
UBE2G2 97.94 215.85 75.79 105.34 148.45 37.37 113.46 
Control 100 100 100 100 100 100 100 
 
Figure 4-2: Average percentage RSV expression, post transfection, after six 
experiments. 
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Mean (SEM) percentage RSV expression, from six experiments, following 
transfection of A549 cells.  
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4.4 Discussion 
The aim of this chapter was to replicate the effect of RNF168 or RFFL 
knockdown on RSV expression seen in Chapter 3. It was also to identify 
whether knockdown of UBE2G2, a protein known to be associated with 
RNF168 and RFFL using InnateDB, had a similar affect on RSV expression. 
Firstly, I showed that RNF168, RFFL and UBE2G2 knockdown by siRNA had 
successfully occurred. RFFL was knocked down most effectively (90 (+/-
1.5)%), followed by RNF168 (77 (+/-10)%) and UBE2G2 (73 (+/-4)%). 
Expression in these cultures was thus less than 30% for each gene, 
matching the knockdown results reported in Chapter 3. 
Previously, I showed that RNF168 and RFFL knockdown had a large effect 
on RSV replication, increasing RSV N gene expression by 415425% and 
588815%, respectively, but with large variation (RNF168, 88-1,245,856%; 
RFFL, 124-1,766,125%). In this series of six experiments, these high RSV 
expression levels were not replicated. RNF168 knockdown induced an 
increase in RSV N gene expression, but by less than two times the control 
and RFFL knockdown actually resulted in a slight down-regulation in RSV N 
gene expression, compared to the control. The variation over the six 
experiments was much less than of those seen previously, suggesting that 
these results may be more accurate.  
It is not known exactly why there was such a difference in RSV N gene 
expression between the previous experiments and the ones undertaken in 
this chapter. They may have resulted from the lack of experience in the 
laboratory during the initial stages of the year, as I did not have any previous 
laboratory skills. The use of different batches of reagents, such as siRNA and 
TaqMan® probes, may also have caused inconsistency within the results. 
Only a slight increase in RSV N gene expression was seen within cells with 
reduced UBE2G2 expression with RSV expression values over the six 
experiments being 113% (37-216%). My results do not support the 
suggestion of a role for UBE2G2 in inhibiting RSV expression and suggest 
that if the E3 ligases, RFFL, RNF168 and TRIM43, do influence RSV 
expression, it may be through an alternative E2 ligase. 
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4.4.1  Preliminary Time Course Results 
Towards the end of the year, I also investigated the expression of UBE2G2, 
RFFL and RNF168 over a number of RSV infected time points, relative to the 
control (non-infected A549 cells at time zero), with gene expression 
normalised to 100%. It is important to note that time zero is two hours after 
RSV infection. The gene expressions were analysed by real-time PCR and 
shown in Figures 4.4 - 4.6 below.  
 
Figure 4-3: Percentage UBE2G2 expression during RSV infection 
 
 
 
 
 
 
 
 
 
 
 
 
Changes in percentage UBE2G2 expression over time in RSV infected epithelial 
cells, relative to the non-infected time 0h control, which was normalised to 100%. 
 
UBE2G2 expression appeared to drop early in the time course before 
peaking >300%, 6h following infection. After this it gradually decreases until 
at 48h, expression was 160% relative to the control. 
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Figure 4.4 shows how the percentage of RFFL changes over time in RSV-
infected A549s, relative to the control of non-infected cells at time 0h. 
RFFL expression was lower than the control over the first 24h of infection. It 
appeared to decrease with time, reaching 27% of the control expression at 
4h following infection. By 48h however, RFFL expression had recovered and 
peaked at 206%. 
 
Figure 4-4: Percentage RFFL expression over a RSV time course 
 
These results show the percentage RFFL expression over time in RSV infection. All 
expressions relative to the control, non-infected time 0h.  
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Figure 4.5 shows how RNF168 levels vary over the RSV time course. Low 
levels of RNF168 expression compared to the control were found throughout 
the 48h time period. Even RNF168 expression in the non-infected 48h time 
point was much lower than the non-infected 0h level.  
 
Figure 4-5: Percentage RNF168 expression over a RSV time course 
 
 
 
 
 
 
 
 
 
 
 
 
This illustrates percentage RNF168 expression over a number of RSV infected time 
points, to investigate how the virus may infect the gene expression. All expressions 
were relative to the control. 
 
These results were only produced from one RSV infected time course. 
Further experiments are required so that statistical analysis can be 
undertaken on the data. If a pattern is observed in gene expression, at 
mRNA level, then protein expression changes can be confirmed through 
western blotting. 
 
 135 
5  GPR34 
5.1 Introduction 
GPR34, an orphan receptor in the rhodopsin-like division of GPCR family, is 
a membrane protein that activates intracellular signals. 
During the knockdown protocol described in Chapter 2, transfected epithelial 
cell cultures were examined under the microscope for morphological 
changes, whenever cultures were taken out of the incubator. The only 
cultures in which morphological changes were seen were in GPR34 
knockdown A549 cells. 
To investigate this phenomenon further, confocal microscopy, an optical 
technique that produces a number of fluorescent images, was used (Section 
5.2.4). GPR34 transfected and non-transfected A549 cells were infected with 
red fluorescent-labelled RSV, so that the effect of these morphological 
changes on RSV infection could be observed. I also investigated where 
GPR34 was located in non-transfected A549 cells. 
5.2 Methods 
5.2.1  Red fluorescent- labelled RSV Infection 
GPR34 knockdown (Section 3.2.1) and non-transfected A549 cells were 
seeded and cultured in two separate T25 flasks until 90% confluent, usually 
48 hours later. Both flasks were washed with PBS. Red fluorescent-labelled 
RSV stock (kindly provided by Dr Mark Peeples, Ohio State University) was 
snap thawed using a water bath at 37oc. 166μl of RSV (MOI of 1) was added 
to 3.834ml of FCS-free medium, and placed into one of the flasks. 4ml of 
FCS-free medium alone was added to the other flask. Both were then placed 
into the incubator at 37oC and 5% CO2 for two hours. 
4ml of supplemented medium was pipetted into each flask, before returning 
them to the incubator for another 48 hours. 
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5.2.2  Microscopic Slide Production 
The cell pellets of GPR34 knockdown and non-transfected A549 cells were 
collected as described in Section 2.1.1 with the cell supernatants collected 
and stored at -20oC. The cell pellets were then resuspended in 5ml of PBS. 
After being mixed well, 1ml of this solution was removed and placed into a 
fresh universal tube with 19mls of PBS. 
Using 50µl of this diluted solution for each slide, we obtained cytospins from 
these samples using a cytospin machine (Speed five for five minutes). The 
slides were then air dried for approximately ten minutes. Each slide was then 
dipped in formalin to fix the cells, which was then washed off fifteen minutes 
later with PBS, prior to being left to air dry again. 
Section 5.2.3 describes the staining procedure followed. Following this, 
coverslips were mounted onto each slide using a fluorescent mounting 
medium (Vectoshield). 
5.2.3  GPR34 Antibody Staining 
Once the cells were fixed and dried on their slides, a Dako wax pen was 
used to draw a circle around them. This made it easier to find the cells and 
prevented reagents from running off the slide. As GPR34 is a 
transmembrane protein, the binding surface must be blocked, so that non-
specific binding of the antibody does not occur. For my experiments I used 
50μl of goat serum blocker on each slide, which was left in a moist, dark 
container for thirty minutes at room temperature. These conditions were 
essential to avoid damage to the cells from light, and to prevent the reagents 
from drying out.  
This blocker was then washed off with PBS twice, before adding 50μl of 
0.5mg/mL Human GPR34 Antibody (Monoclonal mouse IgG2A; R&D 
Systems), diluted in sterile PBS, to the slide. For each experiment, a negative 
control slide was made using 50μl of Human Cytokeratin Monoclonal mouse 
IgG2A Antibody (1 in 200 dilution; 0.1 mg/mL; BD Biosciences). These were 
left in the same dark, moist container for three hours at 4oC.  
 137 
Slides were then washed twice again with PBS, before adding 50μl of Texas 
Red Secondary Antibody (Goat anti-mouse IgG; 1:400 dilution; 0.5mg/mL; 
AbCam) for 30 minutes at room temperature in the dark, moist container. 
The cells were washed again twice with PBS and 50μl of DAPI, at 1:10,000 
dilution (1mg/mL; Sigma), pipetted onto each slide for three minutes before 
being quickly washed off twice with PBS. 
This same protocol was used for A549 cells transfected with the GPR34 
siRNA and for Red RSV infected A549 cells. 
5.2.4  Confocal Microscope 
Confocal microscopy is an optical technique that uses illumination and 
pinhole light sources to remove out-of-focus glare. Using this technique, it is 
possible to produce single-, double-, and triple-labelled fluorescent images 
using red, green and blue colours. These colours depend on which 
fluorescent label has been used on the cells. The colours used during these 
experiments were red and blue with a Texas Red Secondary selected to 
attach onto the GPR34 antibody, and the blue DAPI stain used to visualise 
cell nuclei. Red fluorescent-labelled RSV was also used to show RSV 
infection. 
5.3 Results 
5.3.1  Morphological changes under light microscope 
The morphological changes seen under light microscopy in GPR34 
transfected A549 cells are shown in Figure 5.1 below. 
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Figure 5-1: Morphological changes in GPR34 knockdown A549 cells on day two 
following transfection (200x magnification) 
 
 
Figure 5.1 continues on to page 139. 
A) 
B) 
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Figure 5-1 Continued Morphological changes in GPR34 knockdown A549 cells on 
day two following transfection (200x magnification) 
 
 
 
C) 
D) 
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Figure 5.1 shows two images of GPR34 knockdown A549 cells (A and C) and two 
images of non-transfected A549 cells (B and D). All images were taken on day two 
of the transfection protocol. All images have been taken at 200x magnification. 
 
In Figure 5.1, two images of GPR34 knockdown A549 cells and two images 
of non-transfected A549 cells are shown, both taken using a light 
microscopy. In non-transfected cells, the normal "cobblestone" appearance 
of A549 cells can be clearly seen, with the cells being at almost 80% 
confluence. The siRNA transfected cells do not have the same overall 
appearance. They seem more disjointed, with a smaller proportion of cells 
attaching to other cells. They are also less than 80% confluent, which 
suggests that they may not be growing at the same rate as the non-
transfected cells. The overall shape of the knockdown cells is also more 
variable and irregular.  
Within the GPR34 knockdown cells, prominent dark cell membranes are 
apparent with extracellular projections visible on a small number of cells. 
These features are not present in the non-transfected samples. Lastly, small 
black spots are also apparent the transfected cell cytoplasms, again not seen 
in the control. 
Figure 5.2 shows images of RSV-infected, GPR34-transfected A549 cells 
compared to RSV-infected, non-transfected, and non-infected and non-
transfected cells.  
It is immediately obvious that the non-infected cells appear healthier than 
those that are RSV-infected. They exhibit a "cobblestone" appearance, and 
are over 100% confluent. The infected cells appear more unhealthy and have 
larger gaps between them. The infected transfected cells look unhealthier 
than the infected non-transfected cells, and again, less confluent, suggesting 
slower growth. They also seem to have a darker appearance and appear 
slightly more clustered, with less defined cell edges. This phenomenon was 
investigated further using red fluorescent-labelled RSV. 
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Figure 5-2: Comparison of infected GPR34 knockdown A549 cells, infected non-
transfected A549 cells and non-infected, non-transfected A549 cells on day five. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
These images were also taken at 200x magnification on the light microscope, but on 
day five of the protocol. The first image is of RSV infected, GPR34 transfected A549 
cells. The second image is of RSV infected, non-transfected A549 cells, and the 
third image is of non-infected, non-transfected A549 cells. 
  
  
 
Infected GPR34 
transfected A549 cells 
Infected, non-
transfected A549 cells 
Non-infected, non-
transfected A549 
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5.3.2  A549 infection with red fluorescent-labelled RSV  
Given the morphological changes observed, we used red fluorescent-labelled 
RSV to determine whether GPR34 knockdown visibly changed the cellular 
response to RSV. 
Figure 5.3 again shows morphological differences between GPR34 
transfected and non-transfected A549 cells, infected with red RSV. In both 
images, it appears that the RSV is located within the cell cytoplasm with the 
nuclei appearing RSV free.  
Overall, the edges of the transfected cells are less well defined. The red 
colour also seems to be less dense at the edges of the transfected cells, 
whereas the colour remains consistent throughout the non-transfected cells. 
The transfected cells also have a more speckled appearance, with unusual 
black spots near the cell membrane. Figure 6.4 shows these changes at 
higher magnification. ‘Blebs’ near or within the cell membrane can be clearly 
seen. 
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Figure 5-3: Comparison of red RSV infected A549 cells that are transfected or non-
transfected with GPR34 siRNA. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A549 cells transfected with GPR34 siRNA or cultured normally, were infected with 
red RSV. After 48 hours, the cells were fixed onto microscopic slides. 
 
 
 
Red RSV infected, 
GPR34 transfected 
A549 cells 
Red RSV infected, 
non-transfected 
A549 cells 
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Figure 5-4: Higher resolution image of the red RSV infected, GPR34 transfected A549 
cells 
 
 
 
 
 
 
 
 
 
 
Figure 5.4 shows Red RSV-infected GPR34 transfected A549 cells, at a higher 
magnification.  
 
5.3.3  Results from GPR34 Antibody 
To determine where the GPR34 protein was located, I used confocal 
microscopy to visualise non-transfected A549 cells stained with a Texas Red 
labelled GPR34 antibody compared to a control antibody staining Cytokeratin 
(Figures 5.5 and 5.6). DAPI was used to visualise the nuclei. 
The figures below clearly show that GPR34 is a transmembrane protein, with 
the red fluorescence being denser around the cell edges in the low 
magnification images. The higher magnification single cell image in Figure 
5.7 shows that GPR34 is clearly within the cell membrane, but also around 
the nucleus with an unusual speckled appearance.  
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Figure 5-5: GPR34 antibody staining 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The image in the top left corner shows non-transfected A549 cells red fluorescently 
labelled with the GPR34 antibody. 
The image in the top right corner shows the  blue fluorescently labelled nuclei using 
the DAPI stain.. 
The third merged image shows GPR34 location relative to the cell nuclei. 
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Figure 5-6: Cytokeratin (control) antibody staining 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Similar to Figure 5.5; the top left image is red fluorescence, the top right image is 
blue fluorescence, and the third image is the double coloured sample. 
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Figure 5-7: GPR34 antibody staining within a single cell 
 
 
 
 
 
 
 
 
 
 
 
 
 
This shows an A549 cell stained with GPR34 antibody, Texas red secondary and 
DAPI. The image has been produced by the confocal microscope. 
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5.4 Discussion 
GPR34 is a membrane protein, which causes a response by triggering 
intracellular signals through the stimulation of heterotrimeric G proteins. It 
was first discovered in 1999, during a search on GenBank for original GPCR 
sequences. GPR34 is located on the X chromosome, and has been 
preserved for 450 million years, as it has been identified in every vertebrate 
species to date. GPR34 is an orphan receptor in the rhodopsin-like subset of 
the GPCR family. To date, no interactions have been found associated with 
this gene (113-115).  
Under light microscopy, GPR34 transfected A549 cells appeared to lose their 
normal 'cobblestone' appearance and were more sparse, suggesting that 
they are not able to grow at the same rate. The transfected cells were also 
more irregular in shape and varied in size. Individually, the cells had 
prominent dark cell membranes, with unusual black spots within the 
cytoplasm. RSV infection of both transfected and non-transfected cells 
resulted in a similar appearance. 
Given this phenomenon, red fluorescent-labelled RSV was used to visualise 
these morphological changes better and to see whether GPR34 transfection 
affected where RSV was located within the infected cell. The images within 
this chapter confirm that RSV infection predominantly occurs within the 
cytoplasm. In GPR34 transfected cells, the red RSV fluorescence faded 
towards the peripheries of the cell, compared to the well-defined membranes 
and consistent red colour observed in the non-transfected cells. The 
cytoplasm of the knockdown cells also had a speckled appearance, with 
black spherical 'outcrops' from the membrane. These blebs may imply that 
GPR34 may have a role in maintaining the internal structure of the cell or in 
maintaining its membrane integrity. Blebbing is also associated with cellular 
apoptosis, and we could be witnessing an accelerated or abnormal apoptotic 
process occurring (170). 
A GPR34 antibody was also used to investigate the location of the GPR34 
protein within non-transfected cells. The red colour was denser around the 
cell edges, suggesting the GPR34 was mainly found within the cell 
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membrane. On imaging a single cell, GPR34 protein was shown within the 
cell membrane, but also around the nucleus. These findings require 
repeating, as this series of experiments was only performed once due to 
pressures of time. Given more time, a Z stack would have been performed on 
the confocal microscope to determine in 3D where in the cell GPR34 was 
located. 
Again, given more time, validation of these results could have been done by 
examining how GPR34 protein levels changed in transfected and non-
transfected cells using Western blots. Immunoprecipitation, a technique that 
allows the isolation of individual proteins or complexes of attached proteins, 
could also have been used to determine whether RSV proteins, such as NS1 
and NS2, attach to GPR34 protein during infection. 
Further work on this protein might include using techniques to increase 
cellular GPR34 protein expression to see how this affects cell morphology 
and the response to RSV infection. MG-132, a proteasomal inhibitor, works 
by preventing protein degradation. It could be used to investigate whether 
GPR34 is degraded through the proteasome or not. If this were to be the 
case, then GPR34 protein expression as measured by Western Blot would 
increase, allowing GPR34 over-expression to be studied. Transfection of 
A549 cells with GPR34 might also allow the influence of higher GPR34 
expression on RSV infection to be studied. Future MPhil students may 
undertake this over the coming year. 
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6  Final Discussion 
The main objective of this MPhil thesis was to determine whether 26 innate 
resistant genes, previously shown by Prof. Tripp at University of Georgia to 
influence Influenza replication, differentially influenced RSV replication in 
airway epithelial cells. 
This was done by ensuring gene expression knockdown, using siRNA from 
Prof. Tripp, was successful in our hands. Gene expression was successfully 
knocked down for eight randomly selected genes by at least 70%. This is 
either within, or better than, the predicted range of 60-80%. Based on these 
studies, the expression for each of the 26 genes given to us by Prof. Tripp 
was knocked down in A549 cells, and then infected by RSV. RSV N gene 
expression was measured in these cultures two days following initial 
infection. Twenty of the genes were found to up-regulate RSV expression 
after knockdown, suggesting that these genes were potentially protective, 
whereas six genes reduced RSV activity post siRNA transfection (Figure 
3.21). 
RFFL and RNF168 were studied further, because knockdown of these genes 
caused a many thousand-fold increase in RSV expression. Unfortunately, 
when these experiments were repeated (>6 times), these findings could not 
be replicated. RNF168 knockdown caused a mean (SEM) RSV N gene 
expression of 180 (+/-51)% and RFFL knockdown caused RSV to be similar 
to that of the non-transfected control. Using the InnateDB database, UBE2G2 
was identified as a common partner for these two E3 ligases and also 
TRIM43. UBE2G2 was investigated as it was thought that it might have an 
important role in RSV replication by knocking down this gene in epithelial 
cells and infecting the subsequent cultures with RSV. To our surprise, this 
made little difference to RSV expression, indicating that it probably does not 
have a significant role in protecting us against RSV infection. 
GPR34 was investigated further because its knockdown caused 
morphological changes to occur in epithelial cells that were observable under 
the light microscope. Unknown dark membranes and spots within the GPR34 
knocked down A549 cells were seen. Red fluorescent-labelled RSV was 
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used to show that blebbing occurred in the siRNA transfected A549 cells, and 
a GPR34-antibody showed that this protein was primarily located within the 
cell membrane. 
Therefore this thesis has succeeded in all of the objectives initially described. 
The results, limitations and potential future research ideas for each chapter 
are as follows: 
6.1 Validation of Innate Resistant Genes in RSV Replication 
using SiRNA Transfection 
In Chapter 3, the percentage knockdown was shown for a group of randomly 
selected genes using siRNA from Prof Tripp. This analysis and calculation 
would have to be performed for other genes if future work were to focus on a 
particular gene whose knockdown had not been already calculated. 
Furthermore, although it is a reasonable presumption that mRNA expression 
is a good surrogate for protein expression, given more time, Western blot 
analysis could be used to show that protein expression correlated with mRNA 
expression.  
Chapter 3 also details how the 26 genes that were knocked down influenced 
RSV N gene expression following infection. In most of these transfected 
RSV-infected cultures, there was considerable variation in RSV expression in 
the three experiments undertaken, which made statistical analysis difficult. 
Whilst every attempt was made to standardise the reagents and the 
knockdown and infection protocol, this variation could have been due to 
minor differences between bathes of reagents or virus (although aliquoted). 
Minor differences in pipette use or similar technical reasons may also have 
contributed. However, also plausible, could be variation in growth rate of 
receptor expression, density of cells used or the cell cycle stage of these 
cells at either transfection or infection stages of the protocol. Cycle stage is 
believed to affect RSV replication and clearly growth rate would influence 
viral replication. Similar variability in knockdown levels obtained were seen 
using an analogous approach to look at susceptibility to flu virus replication 
by R. Tripp (Personal Communicator) who standardised by using a larger 
number of replicates. 
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How the results documented in this thesis relate to infants with RSV 
bronchiolitis is a reasonable question to ask. These findings further our 
understanding of the pathogenesis of RSV disease, and also highlight 
avenues for future therapeutic research, which might possibly involve 
increasing expression of these ‘innate resistance genes’ in the respiratory 
epithelium.  
6.2 Further studies of RFFL and RNF168, and identification 
of UBE2G2 
InnateDB is an online database that demonstrates interactions and pathways 
between proteins important in innate immunity. This was used to investigate 
possible protein-protein interactions possibly relevant to RSV infection. 
UBE2G2, an E2 ligase, was identified as a common partner for RNF168, 
RFFL and TRIM43 (Figure 3.22). As RNF168 and RFFL knockdown showed 
a high increase in RSV N gene activity, and TRIM43 knockdown up-regulated 
the RSV expression by over three times the control, it was decided to 
investigate UBE2G2 further.  Firstly, efficient knockdown had to be proved 
and over six experiments the average gene expression knockdown was 
73.40%, easily within the predicted range of 60-80%. Consequently, RSV N 
gene expression was analysed, over six experiments, giving an overall 
average of 113.46% (Figure 4.2). The variation of this expression was 
between 37.37% and 215.85%. Therefore, these results do not support the 
suggestion that UBE2G2 could have been a key component of the RSV 
pathway. RFFL and RNF168 were also included in these six experiments to 
try and prove the high RSV N gene expressions found in the three initial 
experiments. Initially knockdown success was proved with the average 
knockdown for RNF168 and RFFL being 77.45% and 90.03%, respectively. 
After knockdown, neither gene could repeat the previous results. RFFL 
knockdown actually caused a slight down-regulation in RSV expression with 
an average value of 96.20%, with the value range between 30.04% and 
145.40%. Whereas RNF168 knockdown displayed an overall up-regulation in 
RSV N gene expression by nearly two fold. Even though this is not close to 
the previous result, the result is encouraging and RNF168 has been 
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investigated further (See Section 6.5). Although the experimental number 
was increased to n=6 replicates, variability was still observed between the 
samples during analysis. As these knockdowns were carried out at the same 
time they cannot be as easily explained by differences in reagent stocks or 
preparations and the variability seen on different days. The reason for this 
remaining variability is difficult to explain unless different number of cells had 
perhaps survived transfection and exposure to Dharmafect. There is clearly a 
further factor involved. This limitation could be addressed by further 
increasing the number of replicated used for each siRNA or protein analysed 
giving larger groups for a more robust statistical analysis and/or by employing 
a robotic system to ensure standardisation of the time each sample was 
exposed to each specific reagent or step during the protocol. 
Throughout this MPhil project, A549 cells, an immortalised cell line, were 
used to gain results. These are easy to grow, standardised and should 
produce results similar to primary cells. Once data has been found though, 
the use of A549 cells, bronchial brushings in RSV-infected and healthy 
infants should be used to validate the findings. Samples from patients are a 
valuable resource, but are not easily accessible in large sample numbers. 
6.3 RSV and RNAi 
Respiratory viruses have been a popular target for siRNA research, with RSV 
being the first of these investigated in this area in 2001.  
Reasons why respiratory viruses, especially, are targeted in this up and 
coming area of study (105, 106): 
1) Many viral sequences have already been identified, easing the 
discovery for potential specific sequences. 
2) Detailed research has occurred on respiratory viruses and their 
optimal conditions for replication are well understood. 
3) Unpredictable epidemics can be caused by respiratory viruses, so if 
siRNA works therapeutically and the side effects are generally known, 
then rapid therapeutic development could occur in emergencies. 
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4) Respiratory viruses are usually targeted by their surface proteins 
which are often variable, so specific siRNAs would be much more 
reliable.  
A common barrier in the production of many medicines, is efficiently and 
effectively delivering the agent. As mentioned above, the respiratory 
epithelium is the first point of contact for RSV within its host. Inhaled delivery 
of siRNA has been a success in targeting this epithelium and then taken up 
by the epithelial cells after one dose. Ribavirin is an example of a successful 
topically delivered antiviral against RSV (105, 106).  
A number of attempts have already been made to find the particular target to 
overcome RSV. An intranasal administered siRNA targeting the RSV P gene 
was shown to significantly reduce RSV spread within mice models, but 
unfortunately this would only defend against one specific strain. When 
“knocking out” the RSV NS1 protein the virus is eradicated but mainly by the 
immune system and host itself rather than the siRNA. Even though this is 
looking promising, it is still unclear about how siRNA could potentially affect 
the immune memory response. SiRNAs may also be tolerated by the young, 
elderly and immunocompromised, which would be essential for management 
against RSV (2, 108).  
ALN-RSV01 is another potential siRNA which inhibits RSV N protein 
expression. So far in research it has shown encouraging results throughout 
murine models with significant lower RSV titres compared to the controls, 
and in the 2009 publication DeVincenzo et al announced its safety in healthy 
volunteers (105, 106, 171).  
6.4 Morphological changes caused by GPR34 
Each day of the siRNA transfection protocol the knockdown A549 cells were 
inspected under the light microscope. The only gene resulting in 
morphological changes after knockdown was GPR34. The images can be 
seen, both after transfection, but pre RSV infection in Figure 5.1, and post 
RSV infection in Figure 5.2. The morphological changes were more apparent 
on day two of the protocol compared to day five. On day two (before RSV 
infection), the GPR34 knockdown A549 cells were compared to the non-
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siRNA transfected A549 cells. The normal "cobblestone" appearance and 
efficient growth was shown in the non-transfected A549 cells. The GPR34 
knockdown cells had more irregular shapes and sizes than those seen in the 
control image. The knockdown cells were not as confluent suggesting that 
they were not growing at the same rate to normal. Within the knockdown 
cells, dark cell membranes, extracellular projections and black spots could be 
seen. On day five (post RSV infection), the GPR34 knockdown cells were 
continuing to grow at a slower rate than the non-knockdown cells. They also 
appeared darker in colour, more clustered with less defined cellular edges, 
compared to the non-transfected cells. The use of red fluorescent-labelled 
RSV was utilised to observe these changes further by investigating under the 
confocal microscope (Figures 5.3 and 5.4). In the GPR34 knockdown A549 
cells, the morphological changes were present as the cells appeared 
speckled, with unusual black spots on the membrane, which has been 
suggested as blebbing, mainly associated with cellular apoptosis. The RSV 
was found within the cell cytoplasm, excluding the nuclei, in A549 cells, but 
the red colour became less dense towards the edges of the cells in 
knockdown cells, compared to the non-transfected sample. Finally GPR34 
was investigated by the use of antibody staining (Figures 5.5 and 5.6). 
GPR34 antibody was stained onto A549 cells fixed on microscopic slides. 
Cytokeratin antibody was used for the control slide. Cytokeratin is normally 
found inside all cells forming a cytoskeleton within the cell, which gives the 
cell its shape. Texas red secondary antibody was used, which works by 
attaching onto the GPR34 antibody and therefore illustrating the location of 
GPR34 in a red colour. This experiment proved that the GPR34 protein is 
found mainly in the cell membrane, but occasionally seen within the nuclei. 
The results for GPR34 are interesting, but validation of these results and 
further techniques are required before it could all be understood. 
Whilst focusing on the confocal microscope, a Z stack could be performed 
detecting the depth distance that GPR34 is present within A549 cells. Also, 
GPR34 knockdown cells could be stained with the GPR34 antibody to prove, 
firstly, that the siRNA is knocking out the protein, and secondly, that the 
antibody is targeting the correct protein. Western Blot technique could be 
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introduced to focus on protein expression, by confirming that the protein 
expression is reduced by siRNA technique and whether there are any normal 
changes in GPR34 protein expression over a number of RSV infection time 
points. Any up- or down-regulation would be observed at protein level. The 
protein is shown up on the Western Blot gel by the use of a GPR34 antibody. 
Immunoprecipitation technique may also be used, which is able to isolate 
proteins from the cell solution. This would be able to determine whether any 
RSV proteins are able to attach onto the GPR34 protein, and are illustrated 
through Western Blot. The use of a proteasome inhibitor (MG-132) could also 
be utilised. This functions by inhibiting protein degradation to investigate 
whether GPR34 is degraded via the proteasome or not. The results are 
proven by Western Blot analysis, to show that protein expression has 
increased, and should therefore cause a reduction in RSV N gene expression 
when analysed by PCR. Another possible way to increase GPR34 
expression within the cells is by transfecting GPR34 protein into the cells. 
6.5 Further investigations for RNF168 
Finally, RNF168 has been investigated further by Dr. B Flanagan (Personal 
Communicator) through a number of techniques. The use of Western Blots 
have shown that RNF168 protein expression reduces over RSV time points, 
and begins to disappear at 24 and 48h post RSV infection. Lilley et al have 
investigated the effect of ICP0, a protein of Herpes Simplex Virus Type I, on 
RNF168, showing similar results, via Western Blot technique, over an 
infection time period. Lilley has also shown that the use of MG-132, 
proteasome inhibitor, causes the protein expression of RNF168 to be 
increased, resulting in the reappearance of RNF168 on the Western Blot gel 
(172, 173). Therefore this suggests that the use of MG-132 may increase 
RNF168 expression during RSV infection. Whilst this technique is taking 
place, further investigation using the confocal microscope can be done. 
Similar to those mentioned for GPR34, a RNF168 antibody could be used to 
investigate where RNF168 can be found in the cell, the efficiency of siRNA 
knockdown and how RSV infection affects the protein, visibly. SiRNA 
knockdown should also be validated through Western Blot to confirm protein 
expression is being reduced, and immunoprecipitation could show any 
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association between RNF168 and RSV proteins. Also, through Dr. B 
Flanagan, an association between H2A histone and RNF168 has been 
found. Through mass spectrometry analysis, H2A histones are shown to be 
less ubiquitinated in RSV infection. H2A histones have been found to be 
ubiquinated by RNF168 in RSV infection, which induces the recruitment of 
DNA repair molecules and enzymes. It is still unclear why this may 
advantage RSV infection, as the virus does not enter the nuclei, whereas, 
interestingly, ICP0 does (172, 173).  
In pharmacology, Bortezomib is the first proteasome inhibitor to become an 
intervention available for humans. It is an anti-cancer drug, indicated for 
multiple myeloma. This is an interesting concept, because proteasomal 
inhibition has been suggested to reduce RSV N gene expression. This 
particular intervention would not be suitable obviously due to its cytotoxic 
effects and non-specificity, but it is exciting to see an intervention produced 
within this area. 
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